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9                  ABSTRACT
Vertebrate skeletal muscles are cross-striated tissues, composed of long, multinucleated cells called
myofibers. These fibers can further be divided into three major elements: the contractile machinery
(myofibrils), membranes and a cytoskeletal network that anchors the myofibrils to the plasma
membrane. The striated pattern of myofibrils arises from the repeated, ordered arrays of thin (actin)
and thick (myosin) filaments, which form the contractile units, sarcomeres. Muscle contraction
occurs when myosin heads in the thick filament interact with actin in the thin filament causing the
two filaments to slide past each other. During the past ten years, the complete sequencing of the
giant sarcomeric protein titin and discovery of several new actin- and myosin-associated proteins
has shed new light on the structure and function of the skeletal muscles. However, the assembly of
the muscle sarcomere is a complex interplay between these proteins and the present picture is still
far from complete.
This study describes the identification and characterization of a novel thin filament protein, termed
myotilin. It  consists of two Ig-like domains flanked by a unique serine-rich amino-terminus and a
short carboxy-terminal tail. Myotilin binds F-actin and efficiently cross-links actin filaments into
large, stable bundles. Myotilin also decreases the rate of F-actin depolymerization in vivo and in
vitro, suggesting that it plays a role in thin filament stabilization. The structural basis for the cross-
linking activity is based on myotilins ability to dimerize via its carboxy-terminal half.
Immunoelectron microscopic studies have shown, that in adult human muscles, myotilin localizes to
the Z-disc, where thin filaments of opposing sarcomeres are cross-connected by α-actinin. Myotilin
directly binds α-actinin and also γ-filamin. Myotilin enhances the affinity of α-actinin for actin
filaments, which increases the size and rigidity of in vitro cross-linked actin bundles. γ-filamin
participates in the early organization of actin cytoskeleton during muscle differentation, although its
final location in the Z-disc might be dependent on the presence of myotilin. The expression of
myotilin is tightly regulated to the later stages of in vitro myofibrillogenesis, suggesting that
myotilin might be involved in myofibril reorganization. Premature expression of myotilin in muscle
cells leads to strong actin bundle formation, which prevents normal assembly of sarcomeres.
Furthermore, properly timed expression of truncated myotilin fragments leads to severe myofibril
disarray. Coinciding, the characteristics of myotilin, i.e. strong actin cross-linking and stabilizing
activity, interactions with key structural components of the Z-disc and precisely regulated temporal
expression, propose a role for myotilin as a "final lock" that provides rigidity and stability to the Z-
disc structure. Mutation in the myotilin gene causes an autosomal dominant form of limb-girdle
muscular dystrophy type (LGMD1A). This  muscular disorder is a late onset disease, characterized
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by progressive weakness of the hip and shoulder girdles. The identified missense mutation in exon
II results in the exchange of the amino acid 57 from threonine to isoleucine. The histological
examination of the diseased muscles has revealed extensive Z-line streaming, which may be an
indication of an altered function of myotilin. The fact that this point mutation causes such a severe
phenotype argues that myotilin has an important structural and/or regulatory role in myofibril
formation and maintenance.
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                             REVIEW OF THE LITERATURE
1. Cytoskeleton in non-muscle and muscle cells
The cytoskeleton in all vertebrate cells is a dynamic, although mechanically stable cytoarchitecture
of three distinct, yet interconnected filament systems: actin microfilaments, intermediate filaments
and a microtubular network 1-3. They all function in concert controlling the cell shape, motility and
cell division. The actin cytoskeleton is largely responsible for cell morphology, locomotion and
muscle cell contraction 1-4. It is composed of polymerised actin filaments with a large group of
different actin-binding proteins 1 and displays many characteristic structures, including stress fibers,
lamellipodia, filopodia and the cortical actin meshwork 5. Additionally, in organized tissues, actin
filaments give rise to thin filaments, which together with thick filaments, form the structural basis
of the contracting subunits 4. In sarcomeric structures, actin filaments are rather stable and precise
in length, whereas in other structures, the filament assembly is dynamic and rapid 6. The actin-
binding proteins can be divided into subclasses, based on their mode of action on F-actin (Figure 1)
1,7.
      Figure 1. Functions of actin-binding proteins determined from in vitro
      experiments. (Adapted from Ayscough, K.,1998)
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Actin monomer (G-actin) binding proteins (profilin, cofilin, twinfilin) have been regarded as
sequestering proteins, which mainly inhibit filament growth, although they have also been reported
to promote actin polymerization and rapid filament turnover 8,9. Several isoforms of these proteins
exist and, thus, the different actions could result from isoform-specific functions. Capping proteins
(capZ, tropomodulin), on the other hand, cap the filament ends and thus take part into regulation of
filament growth 10,11. Proteins responsible for actin filament disassembly (e.g. gelsolin), sever and
cap the fast-growing (barbed) ends of the filament and their rapid activity is regulated by Ca2+ and
phosphatidylinositol 4,5-bisphosphate (PIP2) 12. The actin-binding proteins listed above are all
somehow involved in the regulation of the filament assembly. However, there are also proteins that,
via their interaction with actin, stabilize the filaments and/or link them together. Tropomyosin, for
instance, forms continuous strands, wrapping around actin filaments in sarcomeric thin filaments.
This structure stabilizes the filament backbone and furthermore, prevents binding of other proteins
where it is not appropriate 4. The higher order structures of actin filaments are formed via actin
cross-linking and/or bundling proteins (e.g. α-actinin, ABP-120, filamin), resulting in tightly
packed bundles or loose filament networks 13. The most complexed association of actin is with
myosin in contracting muscles. The interaction is regulated by Ca2+ and it involves local
dissociation of other proteins (tropomyosin and troponinI) from the filament surface 14.
The most common module encountered in F-actin binding is a tandem repeat of two calponin-
homology (CH-) domains of the villin protein family 13,15. α-actinin, for instance, together with
dystrophin, spectrin and utrophin, utilizes the CH-domains to bind actin. However, in proteins like
titin and kettin,  intracellular, C2-type of Ig-like domains have been  found to be responsible for
actin binding 16,17.
2. Structure and function of skeletal muscles
The vertebrate musculature is composed of three different types of muscles. Smooth muscles, as the
name implies, are non-striated muscles, mainly found in the vascular system, digestive tract and in
uterus. Cardiac muscle, instead, is a striated, contineously contracting muscle taking care of blood
transport.  The second class of striated muscles enables an organism to move (skeletal muscles) and
to breath (diaphragm). Skeletal muscles are organs specialized for rapid force production. They are
composed of long, multinucleated cells termed muscle fibers (Figure 2). A human adult muscle
fiber is typically 10 to 100 µm in diameter and it can reach tens of centimeters in length 18. These
fibers are further composed of three major components: myofibrils, membranes and a cytoskeletal
network, which anchors the contractile fibrils to the plasma membrane (sarcolemma). The striated
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pattern of myofibrils arises from the repeated, ordered arrays of thin (I-band) and thick (A-band)
filaments, which form the contractile units, sarcomeres. Thin filaments are polar structures mainly
composed of  actin filaments of equal length and actin-associated proteins, which bind along the
filaments or cap the filament ends 4. In the middle of the I-band is the Z-disc, where thin filaments
of opposite directions are linked together by α-actinin dimers 19. Thick filaments are polymers of
myosin molecules assembled into a filamentous backbone with globular heads in an array on the
filament surface 20. Thick filaments contain also several myosin-binding proteins, most of which are
involved in thick filament achorage in the M-line 21. Both thin and thick filaments are connected to
titin molecules, which form the third filament assembly of myofibrils 22. Titin is a giant protein
expanding to half of a sarcomere, from Z-disc to M-line 23,24. It is thought to function as a spring
and a ruler defining sarcomere length after muscle contraction. Nebulin, another large actin-binding
protein, is thought to have an equal role in regulating the length of thin filaments 25-27.
 
Figure 2. A. Structure of a skeletal muscle fiber. Myofibrils, composed of sarcomeres, are
surrounded by the sarcoplasmic reticulum (SR) and plasma membrane (sarcolemma). Near the A/I
junctions, terminal cisternae and T tubules form triads, which regulate the Ca2+ transport and
release. B. Electron micrograph of human skeletal muscle. The A-band is the thick filament region
of the sarcomere, whereas the I-band is composed of thin filaments. The Z-line anchors thin
filaments from opposing sarcomeres and myomesin connects thick filaments to titin in the M-line.
(Adapted from van der Ven, P.F.M., 1995 and Stryer, L., 1981)
A. B.
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Muscle contraction occurs when myosin heads in the thick filament interact with actin in the thin
filament causing the two filaments to slide past each other. The contractile apparatus is regulated by
tropomyosin and troponin complex, which is composed of troponin T, troponin C (calcium-binding
subunit) and troponin I (inhibitory subunit) 28. In resting muscle, troponin I interacts with
tropomyosin and actin, thus preventing the interaction between actin and myosin. Contraction is
activated by the binding of Ca2+ to troponin C, which in turn causes a local dissociation of troponin
I from the actin filament. This further shifts the location of the tropomyosin strand on the actin
filament and makes the myosin binding site fully available 29. Subsequently, thin and thick
filaments slide along each other, driven by hydrolysis of ATP to ADP 14,30. The force generated by
the contracting subunits is further transduced through the plasma membrane (sarcolemma) via
integrin and dystrophin associated molecules to the extracellular matrix, leading to contraction of
the muscle. Transport and storage of Ca2+ ions inside the myofibers is regulated near the A/I
junction of sarcomeres by so-called triads, which are formed from terminal cisternae and several
tubular invaginations of the sarcolemma, termed T-tubules 31.
3. Sarcomeric structure of myofibrils
3.1. Thin filament
3.1.1. Actin
The major component of a thin filament is actin, a globular 42 kD protein, which forms long
polarised filaments. In vertebrate muscles, each actin filament contains approximately 360
monomers twisted in a left-handed helix with 13 monomers in six turns 20. Actin monomers are
composed of four subunits. Subunits 3 and 4 are involved in the association between monomers,
whereas myosin heads and many actin-binding proteins bind to subunits 1 and 2 and thus occupy
outer edges of the filament. In vitro, actin filaments polymerize at both ends until the critical
concentration is reached and at that point, the length distribution of the filaments becomes
exponential 4. Skeletal muscle thin filaments, however, show striking uniformity in their length (1.1
+  0.3 µm in rabbit psoas muscle), 32 suggesting tight length regulation during their filament
assembly. In fact, several proteins are known to participate in thin filament assembly, including
tropomyosin and troponin 33, capping proteins, capZ and tropomodulin, 4,34, α-actinin 19 and
nebulin 26,27 (Figure 3).
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Figure 3. Protein organization in the muscle sarcomere. Thin filaments are
shown in green (actin) and thick filaments in brown (myosin). Thin
filament ends are capped by capZ (pink) and tropomodulin (red). Titin
molecules (blue) extend from Z-disc to the M-line, where they overlap.
Thin filaments are anchored at the Z-disc by α-actinin (gold) and thick
filaments are connected to titin via myosin-binding proteins (yellow).
(Adapted from Gregorio & Antin, 2000)
3.1.2. Tropomyosin and troponins
The backbone of thin filaments is composed not only from actin, but also from two tropomyosin
polymers lying along the helices and from troponin complexes bound to every tropomyosin
molecule 33. Tropomyosin molecules are α-helical proteins composed of two chains linked end to
end and forming continuous strands along actin filaments (Figure 4) 35. Tropomyosin functions in
modulation of the actin-myosin interaction and also in stabilization of the actin filament structure36.
Troponin is a complex of two globular subunits, troponin I and C (TnI and TnC), and one rodlike
subunit, troponin T (Figure 4). TnT interacts with tropomyosin and anchors TnI - TnC to thin
filament. TnC is the subunit responsible for binding Ca2+ -ions, whereas TnI is an inhibitory domain,
which in the absence of Ca2+ -ions, interacts with actin and inhibits the actomyosin ATPase activity
37,38. Tropomyosin binds troponin and actin with a stoichiometry  of 1Tm / 1Tn / 7 actin monomers
39. In relaxed state, Ca2+ -free troponin strongly binds Tm-actin and tropomyosin strands sterically
block myosin interaction with actin filaments. Upon activation Ca2+ -ions bind to TnC causing a
local dissociation of TnI from actin-tropomyosin and subsequent movement of tropomyosin
molecules, which allows actin-myosin interaction leading to filament sliding 14,33,39.
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Figure 4. Protein organization in the thin filament. The double-
stranded actin filament is covered by tropomyosin strands. Each
tropomyosin molecule binds one troponin complex, composed of
troponin T, I and C. The pointed end of the filament is capped by
tropomodulin. (Adapted from Fowler, VM., 1996)
3.1.3. Capping proteins, tropomodulin and capZ
Striated muscle thin filaments are relatively stable and precise in length, which has inspired the
search for protein interactions behind the length regulation 4. Proteins associating with the fast-
growing (barbed) end of the thin filament have been extensively studied and the barbed-end capping
protein, capZ, was discovered in 1986 10. In contrast, the regulation of the slow-growing (pointed)
end remained unclear until tromodulin, a tropomyosin-binding protein was found to cap the pointed
ends of thin filaments (Figure 4) 40. CapZ is an αβ-heterodimer composed of 36 and 32 kD
subunits, respectively 10. It associates with the barbed ends with high affinity at the Z-line and
prevents actin monomer association and dissociation 41. The affinity of capZ for actin is decreased
in the presence of PIP2 42. CapZ binds also α-actinin at the Z-disc, but the biological function for
this interaction is still unclear 43. Recent studies on the function of capZ during myofibril formation
have shown the importance of this protein in regulation of thin filament assembly. CapZ
incorporates to nascent Z-bodies before mature actin striations are formed and inhibition of CapZ
during myofibrillogenesis causes a delay in the organization of actin in I bands 44. Furthermore,
expression of mutated or non-sarcomeric  isoform of CapZ leads to severe sarcomeric disruption
and causes cardiomyopathy in transgenic mice 45,46. Tropomodulin is the pointed-end capping
protein regulating actin filament growth and maintaining the precise length of thin filament 40. It
was originally isolated from  the erythrocyte membrane skeleton as a 43 kD tropomyosin-binding
protein 4. Later, a skeletal muscle specific isoform was discovered 47 and was shown to inhibit actin
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filamentation in the presence of tropomyosin and troponin 48. Inhibition of tropomodulin´s actin-
capping activity  leads to drastic elongation of thin filaments from their pointed ends 11.
Tropomodulin  has been shown not to cap only actin filaments but also the tropomyosin polymers
on the thin filament. In the absence of tropomyosin the affinity of tropomodulin for pointed ends
decreases 49 tropomyosin-actin interaction  is essential for proper tropomodulin assembly 50.
Tropomodulin achieves its sarcomeric location later than most of the thin filament proteins and  it
does not associate with actin filament pointed ends in non-striated premyofibrils suggesting that
there might be another tropomodulin-binding protein required for proper targeting of tropomodulin
to the  pointed ends 50. In fact, quite recently the large actin-binding protein, nebulin, was found to
interact with tropomodulin at the pointed end 51.
3.1.4. Nebulin and nebulette
Nebulin is a large (600-800 kD) actin-binding protein, that spans the entire length of a thin filament
and is regarded as a ruler protein regulating thin filament length during muscle contraction 52. The
extreme C-terminus, containing a Src-homology (SH3) domain,  is inserted in the Z-disc, where it
has been proposed to interact with α-actinin 53. The N-terminus of the molecule is anchored to the
pointed end via interaction with tropomodulin 51. The majority of the protein  (97 %)  is composed
of about 185 copies of  35-residue modular repeats, organized into super-repeats of seven domains
following the unit periodicity of actin/tropomyosin/troponin 54-56. A single repeat with a central
SDXXKY consensus motif is the smallest unit sufficient for actin-nebulin interaction suggesting
that the whole molecule might represent a spring with about 200 actin binding domains along the
protein 57-59. Nebulin has been proposed to lie in the central groove between actin filament strands
occupying the phalloidin-binding site, where it could bridge and stabilize the actin strands 58.
However, Wang and his coworkers have shown, that nebulin associates with the N-terminal
subdomain 1 of actin and would thus wrap around the outer edges of actin filaments where also
tropomyosin, myosin heads and many actin-binding proteins are known to bind 57,60. This location
would mean that, during filament sliding, nebulin has to shift its position on the actin filament
analogously to the troponin/tropomyosin polymer 52. Other functions for nebulin have also been
proposed, as recombinant nebulin fragments can inhibit both actomyosin ATPase activity and
filament sliding and some fragments cross-link actin filaments 59,61.
Cardiac muscle thin filaments are known to have much wider thin filament length distribution than
skeletal muscles and they do not contain nebulin 34. Instead, a smaller, 100 kD nebulin-like protein,
nebulette, has been isolated from avian cardiac muscle 62. Comparison of the primary structures has
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suggested, that nebulette would be  a functional homoloque to the last 100 kD of nebulin´s COOH-
terminus, which involves the integration of nebulin into the Z-discs 63. Nebulette differs from
nebulin mostly in the length and structure of the repeat area: the 35-amino acid module is repeated
only 23 times in nebulette and the modules are not organized into super-repeats. As nebulette is also
too short to span up to the pointed end of the thin filament, it most probably exerts a different
function in cardiac muscle than nebulin in skeletal muscle.
3.2. Thick filaments
3.2.1. Myosin
Human striated muscle thick filaments are 1.6 µm long, bipolar, spindle-shaped structures
composed of ~300 myosin molecules 64,65. A single myosin molecule (530 kD) is a hexamer of two
heavy chains (MHC, 220 kD each) and four light chains (MLC, 20 kD) 66-68. The C-termini of the
heavy chains are α-helical and by twisting around each other, they form a stable, rod-like coiled-
coil tail 68. The N-terminal part of each heavy chain folds to one globular head, which is associated
by two light chains. During thick filament assembly, myosin tails form the filamentous backbone
leaving the headpieces in a helical array on the filament surface 20,68. The packing of the myosin
rods is antiparallel in the middle of the filament leading to a so-called ´bare-zone´, which does not
contain myosin heads 69,70. Outside this region, packing is parallel and forms the two cross-bridge
regions of opposing polarities 70. The assembly of thick filaments and myofibrils has been found
possible also in the absence of myosin heads 71. However, it  results in abnormalities in thick
filament and sarcomere length and affects the shape of myofibrils. In addition to the structural role
in thick filaments, myosin has an important function as a molecular motor in muscle contraction.
The globular headpieces of myosin have ATPase activity and carry the hydrolysis products 14,20. In
muscle contraction, the force and movement are produced through a conformational change in
myosin heads 14.
3.2.2. Myosin-binding proteins
In addition to myosin, vertebrate thick filaments contain a small amount (up to 15 %) of additional
proteins, discovered as copurifying components in myosin preparates 72. All myosin-binding
proteins discovered thus far, i.e. MyBP-C and –H, M-protein and myomesin, belong to the large
immunoglobulin superfamily and are composed of C2 type Ig-domains and fibronectin III-like
(fnIII) repeats 73. At least three MyBP-C isoforms, specific for slow (also known as MyBP-X), fast
and cardiac muscles, have been detected 74,75. A smaller myosin-binding protein, highly
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homologous to MyBP-C, was discovered later and designated as MyBP-H 76,77. C-protein isoforms,
together with the H-protein, form a subfamily of structural thick filament proteins 77,78. The
myosin-binding site, together with titin-binding site, resides in the C-terminus of MyBPs and
myosin binds MyBPs via two different domains, both located in the rod-domain 79-83.  In the A-
band, MyBPs are arranged  regularly in 11 transverse stripes at 43 nm intervals 77,84,85. MyBP-C is
present in the outer 7-9 stripes in all striated muscles, whereas the distribution of different isoforms
and MyBP-H depends on fiber type 77. The presence of MyBP-C in thick filaments leads to
uniformity of the filament diameters and to greater compactness of the filament 86. Furthermore,
deletion of the myosin and/or titin binding sites from MyBP-C causes disappearance of sarcomeric
cross-striations in skeletal myotubes 81 and in cardiac cells of transgenic mice, it leads to severe
myofibrillar disarray 87.
Another subgroup of myosin binding proteins includes myomesin and M-protein, both of which are
implicated in anchoring thick filaments to titin in the M-line 88-90. Both proteins are composed of
seven Ig-domains and five fnIII-repeats arranged in a conserved pattern and the N-terminal domains
are separated by two unique insertions 91,92. The myosin interactions involve the head domain and
the first Ig-domain of myomesin and two N-terminal Ig-domains (2-3) of the M-protein, whereas
the binding site in myosin is in the same distal part of the rod for both proteins 90,93,94. While
myomesin is found in all striated muscle fibers, M-protein is restricted to fast skeletal and cardiac
muscle fibers suggesting that myomesin is involved in the general control of A-band structure and
M-protein is required to accommodate greater stress in fast and cardiac fibers 95-97.
3.3.  Titin
In addition to thin and thick filaments, a third filament structure composed of a giant protein, titin
(also known as connectin), contributes to the assembly, maintainance and function of the myofibrils
98-100. A single titin molecule spans half of the sarcomere having its N-terminus associated with the
Z-line and its C-terminus to the M-line 73. Full-length titin (3000 kD) is a polypeptide of 27 000 to
34 000 residues encoded by a single gene on chromosome 2q 55,101. Several isoforms of the protein
exist and they all result from alternative splicing 102. The highly modular structure of titin is
composed of up to 166  immunoglobulin-like (Ig) and 132 fibronectin III-type (FnIII) domains,
interrupted by sequence insertions at both ends of the molecule 55. Several sarcomeric proteins,
including α-actinin, actin, telethonin/T-cap, myosin, C-protein and myomesin, have been identified
as titin binding partners 103-108. These multiple interactions propose multiple roles for titin: the main
function seems to be to serve as a spring providing both elasticity and passive tension to the
20
sarcomeric assembly. However, the role of titin in the assembly and anchorage of thick filaments is
also crucial and leads to proper centering of the A-band in the middle of the sarcomere 20.
        Figure 5. The layout of a titin molecule. (Adapted from Labeit & Kolmerer, 1995)
3.3.1. I-band titin
The I-band portion (800 – 1500 kD) of titin comprises only tandemly arranged Ig-like repeats with
two intervening sequences 55,109,110. Telethonin / Tcap interacts with two N-terminal Ig-domains of
titin and anchor the I-band portion of the molecule to the Z-disc 107,108. At the central Z-disc, third
and fourth N-terminal Ig-domains are separated by unique 45-residue Z-repeats 109. Up to seven Z-
repeats are found in human striated muscles: the flanking repeats are common to all titin isoforms,
whereas the central repeats are alternatively spliced and vary in different muscle types 109. The
variability in the number of Z-repeats has been suggested to contribute to actin-titin cross-links and
thus to the thickness of the Z-disc in striated muscles 111,112.
The regions of proximal and distal Ig-repeats in the I-band are separated by a PEVK-domain,
especially rich in prolines (P), glutamic acids (E), valines (V) and lycines (K), flanked on either side
by serially linked Ig-domains 110,113. The length of this region can vary from 163 residues in cardiac
muscle to 2174 residues in skeletal muscle 102 and it is known to provide elasticity and passive
tension to titin molecule 113-117.
3.3.2. A-band titin
In the A-band, titin is an integral component of the thick filament, regulating exact myosin
assembly 118. The A-band portion of titin contains both Ig- and fnIII-repeats arranged into distinct
modules 73. In the middle of the A-band is the M-line, where titin filaments from opposing
sarcomere halves fully overlap 90 and the overlapping ends are connected to myosin filaments by
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their interactions with myomesin and M-protein 89,90,93,94. The importance of the M-line
ultrastructure was highlighted as it was found to correlate with contraction speed in skeletal muscles
and with heartbeat frequency in cardiac muscles 119. Myomesin is a structural protein of all striated
muscles, whereas M-protein is restricted to muscle fibers that have to tolerate greater strain (fast
and cardiac fibers) 95-97. The binding site for myomesin is adjacent to a KSP-module, which is
composed of four tandem copies of lycine, serine and proline 55,90. This region is a potential
substrate of an unknown serine/threonine kinase and KSP phosphorylation might thus regulate titin-
myomesin interactions 120. In addition to the structural role of titin, it has also been found to exert
catalytic activity 121. A serine/threonine kinase domain is located at the edge of the M-line and it is
known to phosphorylate a Z-disc protein, telethonin 55,121. In differentiating myocytes, the titin C-
terminus and telethonin co-localize in forming premyofibrils, which proposes a role for titin kinase
in controlling the sarcomeric assembly 121,122.
3.4. Z-disc
3.4.1. Structure of the Z-disc
In the middle of the I-band is the Z-disc, where thin filaments of opposing sarcomeres are cross-
linked together (figures 2 and 3) 4,19,20. Within the Z-disc thin filaments are arranged in a tetragonal
lattice overlapping each other and the width of the Z-disc is determined by the degree of filament
overlap 123. The structure of the Z-disc contributes to the force transmission between sarcomeres
and it is involved in regulation of contractile and elastic properties of muscles 123. Electron
micrographs of longitudinal muscle sections show a zigzag density profile for the Z-disc, which can
vary from 1 layer (a single Z-line) to 2-4 layers depending on the muscle type 19,123 or even up to 10
or more in diseased muscle of nemaline myopathy 124.
3.4.2. Z-disc components
The cross-connecting filaments are thought to consist primarily of α-actinin dimers together with
titin and some other, yet unknown components 4,19,20. The N-terminal portions of titin filaments
extend across the Z-disc, overlap each other and a novel Z-disc protein telethonin (known also as T-
cap) anchors them to the Z-disc 107,108. Recently, other Z-disc proteins have been identified, like
actinin-associated LIM-protein (ALP) 125, γ-filamin 126, myopalladin 127, ZASP 128 and FATZ (also
known as myozenin and calcarcin) 129-131 and also the N-terminus of nebulin is anchored to the Z-
disc53,111,132. FATZ has been recently found to function as a linker protein connecting calcineurin,
an important calcium-dependent protein phosphatase, to the Z-disc and most probably is not
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primarily involved in the structure of the Z-disc 130. Although ALP and ZASP  are known to bind
α-actinin, their contribution to the Z-disc assembly has not been resolved yet. The interaction of
nebulin with α-actinin is unclear and recently, nebulin was proposed to be tethered to the Z-disc via
interaction with myopalladin 127.
3.4.3. α-actinin
α-actinin is a major actin cross-linking protein both in non-muscle and muscle cells 133. It is a 100
kD rod-shaped molecule, composed of an N-terminal actin-binding domain (ABD), a central rod
with four spectrin-like repeats and a C-terminal EF-hand, which binds Ca2 +-ions via two
calmodulin-like domains (Figure 6) 134. It belongs, together with spectrin, dystrophin and utrophin,
to a family of actin-binding proteins, which all share the same modular structure, with a variable
number of central spectrin-like repeats 134,135. α-actinin forms an  antiparallel dimer via the
spectrin-like repeats and thus the actin-binding sites are located at both ends of the proteins 13,136. In
humans, four α-actinin genes have been detected so far: ACTN1 encodes for non-muscle α-actinin,
ACTN2 and ACTN3 for sarcomeric isoforms and ACTN4 for smooth-muscle isoform 137-139. The
sarcomeric isoforms are highly homologous and they are both found in skeletal muscles, whereas
only α-actinin-3 is expressed in cardiac muscle. The actin binding activity of α-actinin isoforms is
differentially regulated: in non-muscle isoforms it is Ca2+-sensitive, whereas in the muscle α-
actinins, part of the EF-hand is alternatively spliced and actin binding does not involve calcium.
The non-muscle isoforms of α-actinin are mainly involved in the organization of actin
microfilaments into stable, parallel bundles 136,140 or in the attachment of actin filaments to the
plasma membrane 141-143. In striated muscles, α-actinin is found only in the Z-line, where actin
filaments of opposing polarity are cross-linked together 133. Whether different α-actinin isoforms
can contribute to the width of the Z-disc, is still unknown.  However, α-actinin 2  and 3 have been
shown to form heterodimers both in vitro and in vivo suggesting similar functional characteristics
for these isoforms  144.
α-actinin binds most of the known Z-disc proteins, including ALP 125, ZASP 128, FATZ  129-131,
myopalladin 127 and titin 102,109,111,145,146 (figure 6).
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    Figure 6. Interactions of α-actinin-2 in striated muscles.
The interaction of α-actinin with titin occurs via two different regions in α-actinin. In the center of
the Z-disc, alternatively spliced titin Z-repeats bind to the extreme C-terminal end of α-actinin and
the interaction has been proposed to be controlled by intramolecular interaction of α-actinin and
PIP2 132. As the number of Z-repeats correlates to some extent with the width of the Z-disc, it has
been proposed to determine the number of α-actinin cross-links and the width of the Z-disc 109.
Furthermore, this particular interaction between titin and α-actinin is likely to be functionally
important, because expression of truncated α-actinin, lacking the extreme C-terminus, leads to Z-
disc hyperthrophy and induction of nemaline-like bodies 147,148. The other titin-α-actinin interaction
occurs in the periphery of the Z-disc, where the fourth N-terminal Ig-domain of titin, together with
the preceeding area, binds to the spectrin-like repeats of α-actinin rod 111. This interaction is
thought to account for the co-localization of α-actinin and titin during myofibrillogenesis, even in
the absence of the C-terminal titin binding site of α-actinin 111,147,148. Although the importance of
titin-α-actinin interactions in the assembly of the Z-disc is widely accepted, some discrepancies still
occur. In the massively enlarged Z-lines of nemaline rods, the organization of individual Z-
filaments is the same as in normal Z-line 124,149. Moreover, the Z-disc portion of titin in nemaline
rods would not be sufficient to extend across the whole Z-line and thus the interactions of α-actinin
and titin cannot be responsible alone for the spacings between α-actinins within the Z-line 4,150.
3.4.4. γ-filamin
 Filamins are ubiquitously expressed actin-binding proteins, present as different isoforms in the
cytoskeleton of various cell types. Until now, three filamin genes have been characterized: FLNA
encodes for  α-filamin (also called ABP-280) 151, FLNB for β-filamin 152,153 and FLNC for γ-
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filamin (also called ABP-L or FLN2) 154. They all are long, rod-shaped molecules, composed of an
N-terminal actin-binding domain followed by 24 C2-type Ig-domains, which are separated by one
or two hinge regions 151,155. The last Ig-domain is involved in filamin dimer formation 151,156. γ-
filamin is expressed only in striated muscles and unlike the other isoforms, it contains a unique
insertion in the middle of Ig-domain 20. γ-filamin has been shown to locate under the plasma
membrane in muscle cells, where it interacts with caveolin-1 and γ- and δ-sarcoglycan 157,158.
Additionally, non-muscle isoforms of filamin are known to bind β1 integrin  at the cell membrane
and because of the high homology between individual filamins, such an interaction could also be
true for γ-filamin 157,159.
In addition to the sarcolemmal location, γ-filamin was found to locate in the Z-disc periphery 126.
Moreover, it is expressed as one of the first myofibrillar proteins, together with α-actinin, during
myocyte differentation in vitro and localizes in the developing Z-bodies and Z-discs. Thus γ-filamin
is involved in the organization of thin filaments in myofibrils.
4. Sarcolemmal membrane and linkage to extracellular matrix
Sarcolemma is the plasma membrane of striated muscle cell. It shares the features and structures
that are common to all plasma membranes. However, the force-producing function of muscle cells
demands extreme stability and also flexibility of the cell membrane, which is gained via unique
protein complexes and multiple intermolecular interactions 160. The importance of the sarcolemma
and its connection to the contracting subunits is highlighted by the fact that defects in proteins
involved in these assemblies cause muscular dystrophy and/or cardiomyopathy161-165. The
connection between the sarcolemmal and extracellular matrix is mediated by two main protein
complexes, the dystrophin-glycoprotein complex and integrins and integrin-associated molecules.
4.1. Dystrophin-glycoprotein complex
The major protein complex responsible for stabilization of the membrane against contraction-
induced damage, is the dystrophin glycoprotein complex (DGC) 166. It is a group of proteins further
divided into three subgroups according to their localization: 1) the intracellular, sub-sarcolemmal
part of the complex is composed of dystrophin, syntrophins and dystrobrevin, 2) the transmembrane
complex comprises the sarcoglycans, β-dystroglycan and sarcospan and 3) the extracellular part
includes α-dystroglycan and laminin-2 (also called merosin) 163,167,168. Dystrophin, together with
the glycoproteins, forms a mechanically strong link between sarcomeres and sarcolemma 169.
Dystrophin is a large (427 kD), rod-shaped cytoskeletal actin-binding protein of the spectrin
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superfamily 170. It is composed of an N-terminal actin-binding domain, long central rod domain
with 24 spectrin-like repeats, a cysteine-rich domain and a C-terminal domain 170,171.
Figure 7. Molecular organization of the dystrophin
glycoprotein complex at the sarcolemma membrane of
striated muscles (Adapted from Betto et al., 1999)
All of the dystrophin domains appear relevant for the function of the protein. Dystrophin locates
along the inner face of the sarcolemma, where it binds F-actin both by the N-terminal region 172 and
the rod domains 173. The cysteine-rich domain interacts with the cytoplasmic portion of β-
dystroglycan thus linking dystrophin to the glycoprotein complex 174. In vitro experiments have
shown, that dystrophin can also bind the cytoskeletal protein talin 175 and the thin filament protein
troponin T 176. The extreme C-terminus of dystrophin has been shown to interact with intracellular
proteins dystrobrevin and syntrophins, although the binding site for γ-actin and α-actinin resides
also in the C-terminus of dystrophin177-180. However, the binding site for syntrophins involves an
alternatively spliced exon in dystrophin and thus suggests possible existence of two functionally
distinct populations of dystrophin with different binding-partners 181. Dystrophin has also a smaller
homologue, utrophin, that is highly similar in primary sequence and secondary structure with
dystrophin. Both proteins associate with the glycoprotein complex at the sarcolemma during fetal
development 182. At birth, dystrophin replaces utrophin at the sarcolemma and utrophin remains
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mainly present at neuromuscular and myotendious junctions 183-185. However, in the absence of
dystrophin, elevated amounts of utrophin can partly compensate the function of dystrophin
suggesting that these two proteins play synergistic roles both in the developing and adult muscles
186-188.
Although dystrophin has multiple interactions through its C-terminus, the functionally most
important one is the tight interaction with β-dystroglycan, which via interaction with α-
dystroglycan forms a link between the intracellular and extracellular compartments of the DG
complex 174. β-dystroglycan is a small (43 kD) single-pass transmembrane protein with an
important role in cell surface matrix organization 189-191. The fact that β-dystroglycan knock-out
mice do not survive their embryonic life, confirms the indispensability of the protein 192. β-
dystroglycan further interacts with  sarcoglycans, a group of relatively small (35-50 kD), single-
pass transmembrane glycoproteins with the main function in DG complex stabilization 163. To date,
five different sarcoglycans, α-, β-, γ-, δ- and  ε, have been described 193-198. Except for β- and ε-
subunits, sarcoglycans are expressed specifically in striated muscles. Sarcoglycans interact in vitro
with each other and also with dystroglycans, although differences between interactions occur 168.
α−sarcoglycan seems to be more loosely associated with the other components and might function
as a separate unit 199, whereas interactions between β-, δ- and γ-sarcoglycans appear particularly
strong 199-201. In vitro experiments have revealed that co-expressed sarcoglycans assemble into a
tight complex before they are targeted to the cell membrane 199. Individually expressed
sarcoglycans, although glycosylated, remain in the internal membranes and do not gain their proper
localization at the cell membrane. Therefore, mutation in any one of the sarcoglycan genes results
in the deficiency of the entire complex 193-196,202. The most recently characterized member of the
DGC is sarcospan, a small (25 kD) unique protein with four transmembrane domains 203. Sarcospan
interacts with sarcoglycans, drives their assembly up to the sarcolemma and stabilizes the
sarcoglycan complex 204.
On the cell surface, the DG complex is eventually bound to the extracellular matrix via laminin-2 /
merosin, a 90 kD extracellular protein specifically expressed in striated muscles 205. Laminin-2 has
also another transmembrane binding partner, α7β1 integrin, which is known to account for an
additional link between cytoskeleton and sarcolemma 191. The other extracellular component of the
DG complex is α-dystroglycan, a large (153 kD) glycoprotein, that links β-dystroglycan and thus
the whole transmembrane portion to laminin 206.
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4.2. Integrins
Integrins are large (90 –180 kD) transmembrane proteins, that form αβ-heterodimers and link
intracellular actin cytoskeleton to extracellular matrix proteins 207. Integrin subunits are generally
composed of a large extracellular portion, a transmembrane segment and a short cytoplasmic tail.
To date, at least 22 different integrin combinations with 8 different β-subunits have been
discovered207.
α7β1 is an important laminin receptor in muscles. The β1 subunit is more widely expressed, while
α7 expression is restricted to skeletal and cardiac muscles 208-210. A knock-out of the mouse α7
subunit produces progressive muscular dystrophy 211. On the other hand, β1 subunit is known to
bind filamin in non-muscle cells with a domain that is highly conserved also in muscle filamin
159,212. Thus the α7β1 integrin complex could provide, in addition to the dystrophin glycoprotein
complex, a second link between laminin and actin cytoskeleton in muscles and participate in
protection against contraction-induced damage 213. The importance of integrins for the structural
integrity of muscles is strengthened by the fact, that expression of α7β1 integrin is elevated in
muscles with dystrophin defects, possibly as an attempt to compensate the missing dystrophin-
glycoprotein linkage 214.
Another important basement membrane receptor, α6β4, has a very different structure and function
in comparison to the other integrins 215-218. Whereas most of the cytoplasmic domains of the β-
subunits are relatively short (~50 residues), the β4 subunit is long (1000 amino acids) and contains
two pairs of fn(III)-like repeats, resembling those that are mainly found in thick filament proteins
219-221. Intracellular interactions of α6β4 are mediated via the cytoplasmic part of β4, which
associates rather with intermediate filament proteins than with members of the actin-containing
cytoskeleton 217,222-224. In fact, α6β4 integrin is part of hemidesmosomes; junctional complexes at
the membrane that anchor intermediate filament cytoskeleton to basement membrane222,223,225,226.
A large protein called plectin, interacts with all cytoskeletal structures (actin, intermediate filaments
and microtubulae), locates also in hemidesmosomes and has recently been shown to interact with
the cytoplasmic tail of  β4-subunit 227. Plectin, together with intermediate filament proteins, plays
an important role in stabilization and strengthening of the cytoskeletal architecture of muscle cells
228 and thus α6β4 integrin serves as a link between IF cytoskeleton and extracellular matrix in
muscle cells218,225,226.
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5. Cytoskeletal structures connecting sarcomeres and sarcolemma
5.1. Actin cytoskeleton
Cytoskeletal structures form a physical link to connect the contracting subunits to the sarcolemma
in striated muscles. Moreover, these connections are needed to maintain the muscular integrity by
redistributing the stress caused by contractile activity. Thus cytoskeletal proteins have also been
found to connect large sarcolemmal adhesion complexes to each other 158. In addition to the
physical role, cytoskeletal structures have been suggested to play an important role in recruiting
signalling molecules between cellular compartments 229.
Recently, novel interactions have been discovered and the molecular organization of the actin
cytoskeleton appears more complex. Interactions of dystrophin with talin and α-actinin, both of
which interact with integrins at the cell membrane 212, can provide additional links between DGC,
integrins and actin cytoskeleton 175,180.
5.2. Intermediate filaments
Intermediate filaments (IFs) have gained their name from electron microscopical observations,
which have revealed that their diameter (10 nm) is intermediate in size when compared to actin
microfilaments (6 nm) and microtubules (25 nm) 230. In striated muscles they form unique
cytoskeletal structures, which are located in the transverse plane of muscle fibers connecting
adjacent Z-discs in parallel 231. Desmin is a 52 kD IF protein, specifically expressed in skeletal,
cardiac and smooth muscles231-234. Expression of desmin has been found as the first landmark in
muscle differentiation and it has been proposed to form the first cytoskeletal structures supporting
the myofibrillogenesis 235,236. Other IF proteins expressed in striated muscles are vimentin,
synemin, paranemin and nestin 3. Nestin and vimentin are actively expressed during early
developmental stages 237. In later stages, the expression of vimentin is completely down-regulated
and nestin is found only in minimal levels, whereas desmin is maintained in mature myofibrils.
Desmin filaments seem to locate not only in a transverse plane, but also in longitudinal planes and
have thus been suggested to integrate the three-dimentional mechanical systems in muscles 238. The
lack of desmin has been found to cause myopathy and cardiomyopathy both in human patients and
desmin knock out mice 239-246. Recently, desmin filaments were found to associate with plectin, a
large multi-functional protein, which interacts with all cytoskeletal structures (actin, intermediate
filaments and microtubules) 247. Plectin is also known to interact with α6β4 integrin complex at the
sarcolemma 227 and thus also intermediate filaments form a connection between intracellular and
extracellular compartments 218,226,247.
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6. Skeletal muscle development and myofibrillogenesis
Skeletal muscle development is a multistep pathway, in which mesodermal precursor cells are
selected to form myoblasts that later are withdrawn from normal cell cycle and subsequently
differentiate. Two families of transcription factors, MyoD and myocyte enhancer factor-2 (MEF2),
play essential roles in this cascade. They bind specific target motifs (CANNTG and an A/T rich
sequence, respectively) in close proximity of muscle specific genes and interact with each other,
which yields to a unique complex that regulates the muscle specific gene activation 248. Both MyoD
and MEF2 transcription factors are targets for diverse intracellular signalling pathways, that control
myogenesis by modulating the function and expression of these factors 249. Myocyte differentiation
and myofibril formation can be studied in vitro using cultured myocytes, although the individual
events are much slower than in vivo differentiation 250. Differentiation in culture is initiated by
serum withdrawal and the progression to mature myocytes takes about seven days 96,250-252.
Expression of desmin is the first sign of muscle differentiation. Subsequently, other proteins taking
part in myofibrillogenesis appear in a precise order and timing of expression 250. Three distinct
forms of myofibrils can be distinguished during the differentiation progress. In the beginning of
myofibrillogenesis, titin and α-actinin appear in a punctate pattern along stress fiber-like structures,
forming premyofibrils 96,235,252. These fibrils are composed of "minisarcomeres", where non-
muscle myosin interdigitates the bipolar actin filaments, which are linked by α-actinin in Z-disc
primordia, called Z-bodies 253. The aminoterminal part of titin is tethered to Z-bodies  and the rest
of the molecule begins to unfold by moving its ends towards forming M-lines 235. Once the C-
termini of titin molecules meet in the region that becomes the future M-band, they are linked up by
myomesin. This structure seems to form a template for thick filament integration into the
sarcomeres and the premyofibrils turn into nascent myofibrils. Other thin filament proteins like
tropomodulin, T-cap, nebulin and γ-filamin 47,126,254 are also expressed at early stages of
differentation and they incorporate into premyofibrils 255. The nascent myofibrils, like the
premyofibrils, have punctate Z-bodies, that are spaced closer (0.3 µm) together than Z-bands of
mature myofibrils (1.4 µm). Thus the growth in sarcomere length and alignment of nascent
myofibrils leads to formation of cross-striated, mature myofibrils 253.
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7. Muscular dystrophies and hereditary myopathies
Inherited muscular diseases are single-gene disorders mainly caused by mutations in genes coding
for muscle specific, structural proteins. These include components of the sarcolemma membrane,
myofibrils and cytoskeletal structures. Alterations in some cytosolic and nuclear proteins have also
been found to cause muscular disorders. The most common inherited muscular disorders  are listed
in table 1. They can be divided into muscular dystrophies and myopathies according to their
clinical, histopathological and genetic patterns 256-259. They are further divided into autosomal
dominant (AD), autosomal recessive (AR), X-linked dominant (XD) and X-linked recessive (XR)
based on whether the gene is located in an autosome or on the X-chromosome and whether the
mutation leads into a dominant or recessive impact 260. Autosomal dominant disease affects males
and females equally and can be transmitted to a child by either parent. Autosomal, recessive disease
is found in homozygotes (or compound heterozygotes), who have gained the defective gene from
both parents and therefore neither of the mutated alleles encodes for a functional protein. X-linked
recessive disorders are more frequent than dominant ones and they affect mainly males, because of
a single X-chromosome. However, a female carrier of an XR disease may manifest symptoms of the
disease to some extent.
Muscular dystrophies are a diverse group of inherited disorders characterized by progressive muscle
weakness and wasting, in which the primary defect is in skeletal muscles. The main groups include
Duchenne and Becker muscular dystrophies (DMD / BMD) and limb-girdle muscular dystrophies
(LGMD). LGMDs include a wide spectrum of genetically and clinically heterogenous diseases with
main manifestations in shoulder and hip muscles. Both dominant (LGMD1) and recessive
(LGMD2) forms have been described, but the dominant forms are less frequent and their symptoms
are less severe than in most recessive forms261.
Myopathies are also a heterogenous group of disorders, usually with a milder phenotype than
dystrophies and clinically characterized by weakness of proximal or distal muscles of the arms and
legs 256. Nemaline myopathies (NEM) are slowly progressive or nonprogressive congenital
disorders with weakness in facial, respiratory and proximal limb muscles 262,263. The diagnosis is
based on the presence of nemaline bodies (rods) in the muscle fibers 264. They are caused by
mutations in thin filament proteins 265-268 and the clinical picture varies from mild childhood onset
to severe congenital forms 269 . Since many of the muscle specific genes are functional both in
skeletal and cardiac muscles, several myopathies and muscular dystrophies are seen in association
with cardiac defects. However, pure cardiomyopathies are not discussed in this thesis.
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Until the end of 1980´s, the classification of inherited muscle diseases was based mainly on the
clinical evaluation of the patient, electromyography and histological analysis of a muscle sample
taken from the patient 270. The main histological findings in dystrophic and myopathic muscles are
alterations in fiber size, necrosis, fiber splitting and accumulation of vacuoles and/or protein
aggregates (rods or bodies) inside the myofibers 271. During the past decade, the genetic and
molecular backgrounds of many muscular disorders has been established and thus the basis of the
old classification was weakened. As the protein alterations behind muscular disorders were
discovered, the diseases were renamed accordingly. Subsequently, novel antibodies against the
muscle specific proteins has made precise protein studies (immunohistochemistry and Western blot-
analysis) possible. Thus the traditional classification is changing and in this review (table 1), the
disorders have been classified according to the cellular location of the altered protein. As this study
involves mainly the structural components of the muscles, only those diseases that affect either
cytoskeletal, sarcolemmal or extracellular matrix components are discussed. Thus metabolic and
mitocondrial diseases of the muscle have been omitted from table 1 and  are not discussed in this
thesis.
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Table 1. Selected, hereditary muscular disorders and gene locations 272           
Disease                                   Inheritance*   Gene locus                 Protein           
Muscular dystrophies
Duchenne / Becker XR Xp21 Dystrophin
Emery-Dreifuss XR Xq28 Emerin
-“- AD 1q11 Lamin A/C
LGMD 1A AD 5q31 (Myotilin / this study)
LGMD 1B AD 1q11-21 Lamin A/C
LGMD 1C AD 3p25 Caveolin
LGMD 1D AD 6q23       ?
LGMD 1E AD 7q       ?
LGMD 2A AR 15q15 Calpain-3
LGMD 2B (Miyoshi myopathy) AR 2p13 Dysferlin
LGMD 2C AR 13q12 γ-Sarcoglycan
LGMD 2D AR 17q12-21 α-Sarcoglycan
LGMD 2E AR 4q12 β-Sarcoglycan
LGMD 2F AR 5q33-34 δ-Sarcoglycan
LGMD 2G AR 7q11-12 Telethonin / T-cap
LGMD 2H AR 9q3-34        ?
LGMD2I AR 19q13.3              ?
VPDMD (allelic to LGMD1A) AD 5q31        ?
Facioscapulohumeral MD AD 4q35        ?
Distal myopathies
Miyoshi myopathy (LGMD2B) AR 2p13 Dysferlin
Distal myopathy with rimmed
vacuoles AR 9p1-q1       ?
Autosomal distal myopathy AD 14       ?
Tibial muscular dystrophy AD 2q31 Titin?
Other myopathies
Bethlem myopathy AD 21q22.3 Collagen VI (α1 or α 2)
AD 2q37 Collagen VI (α 3)
Oculopharyngeal MD AD 14q11-13 Poly A binding protein 2
Epidermolysis bullosa+MD AR 8q24-qter Plectin
Desmin-related AD 11q22 α B-crystallin
-“- AD/AR 2q35 Desmin
XMEA XR Xq28       ?
Congenital myopathies
Myotubular myopathy XR Xq28 Myotubularin
Central core AD 19Q13.1 Ryanodine receptor
Nemaline myopathy AD/AR 1q21-23 α-Tropomyosin
AR 2q21-22 Nebulin
AD/AR 1q42.1 Skeletal α actin
AR 19q13.4 Troponin T
AD 9p13 β-Tropomyosin
Fukuyama CMD AR 9q31-33 Fukutin
α7 integrin CMD AR 12q13 α7 integrin
Congenital muscular dystrophy
with merosin deficiency AR 6q2 α2 laminin
* XR, X-linked recessive
   AD, autosomal, dominant
   AR, autosomal, recessive
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7.1. Alterations in dystrophin-glycoprotein complex
Identification of dystrophin and subsequent characterization of the dystrophin-glycoprotein
complex were the first steps towards clarification of the molecular mechanisms behind various
muscular diseases 170,273,274. The importance of the DGC link between actin cytoskeleton and the
extracellular matrix was soon discovered and disruption of this link was found causative to several
muscular disorders. The most common types of muscular dystrophies, Duchenne (DMD) and
Becker (BMD) muscular dystrophies, were found to be caused by alterations in the same dystrophin
gene 275,276. In Duchenne MD, gene defects prevent expression of the protein, which leads to
severe, early onset muscular dystrophy and cardiomyopathy 258. In patients with BMD, gene
mutations either reduce the level of dystrophin or produce truncated, partially functional
polypeptides and thus the clinical phenotype is milder than in DMD patients 258,275,277.
Mutations in α-, β-, γ- and δ-sarcoglycans cause LGMD2D 202, LGMD2E 193,194, LGMD2C 196 and
LGMD2F 195, respectively.  This group of LGMD2 disorders has also been referred to as
sarcoglycanopathies 258,259. Sarcoglycans are known to assemble together and a mutation in a single
sarcoglycan gene results in deficiency of the entire complex 199. No mutations in the human
sarcospan gene have been detected thus far and interestingly, mice that are lacking sarcospan,
maintain the sarcoglycan complex at the sarcolemma and do not develop muscular dystrophy 278.
However, mice lacking β-sarcoglycan, lose the whole sarcoglycan complex and sarcospan 279.
7.2. Alterations in the sarcolemma and in the extracellular matrix
In addition to dystrophin glycoprotein complex, a second link between laminin and actin
cytoskeleton in muscles is formed via α7β1 integrin complex 213. In muscles with dystrophin
defects, expression of α7β1 integrin is elevated resembling an attempt to compensate the missing
dystrophin-glycoprotein linkage 214. Recent studies have shown, that mutations in α7β1 integrin
gene cause congenital myopathy, characterized by very early onset and delayed motor milestones
280. The large multifunctional protein, plectin, interacts with all cytoskeletal structures (actin,
intermediate filaments and microtubulae) and recently, it has been shown to interact with α6β4
integrin complex at the sarcolemma 227. Plectin, together with α6β4 integrin and intermediate
filament proteins like desmin, forms a third connection between intracellular and extracellular
compartments 218,226,247. Accordingly, a skin disease called epidermolysis bullosa with muscular
dystrophy, is caused by mutations in the  plectin gene281 and alterations in desmin gene result in
autosomal dominant or recessive myopathies  243,282.
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Other sarcolemmal defects include mutations of caveolin-3, which results in LGMD1C 283,284, and
dysferlin, a large transmembrane protein, whose mutations result in two distinct phenotypes,
LGMD2B and Miyoshi myopathy 285,286. Caveolin-3 is the major component of caveolae, which
are special microdomains of the sarcolemma. Mutations in caveolin-3 have been suggested to
disrupt the formation of caveolae, thus leading to unstable caveolin aggregates, which are retained
within Golgi complex and are not targeted to the sarcolemma 287. Patients with caveolin-3
deficiency show mild to moderate proximal weakness with early onset 284. Dysferlin is a 230 kD
integral component of the sarcolemma and it is absent in patients with LGMD2B. The molecular
mechanisms behind this disease remain unclear 288,289.
Defects in extracellular components laminin-2 and collagen VI are known to cause congenital
muscular dystrophy and Bethlem myopathies, respectively 290-293. The first evidence, that laminin
deficiency could lead to muscular dystrophy was gained from a murine muscular dystrophy strain,
dy2J, which was found to have a point mutation in laminin α 2 chain gene294. Classical CMD, on
the other hand, is a severe, early onset disease and 50 % of the patients show primary defect in the
laminin α2 chain, although partial absence of the N-terminus of the α2 chain has also been
associated with a milder form of muscular dystrophy 291,295,296. In skeletal muscles, laminin-2 is
known to interact both with α-dystroglycan of the DG complex and α7β1 integrin and thus the
absence of α2 chain leads to severe changes in the sarcolemma and extracellular matrix
191,210,280,297.
7.3. Alterations in sarcomeric proteins
Only few skeletal muscle disorders are associated with myofibrillar defects, whereas a majority of
inherited cardiomyopathies are almost exclusively caused by mutations in sarcomeric proteins
162,165,258.The autosomal recessive form of LGMD type 2G is caused by mutations in telethonin,
which is known to link titin to the Z-disc 107,108,298. Titin is a candidate for tibial muscular
dystrophy, which has been mapped to a region spanning the titin locus on chromosome 2q31 299.
The other large sarcomeric protein, nebulin, is found mutated in autosomal, recessive nemaline
myopathy 267,300. Mutations in two genes encoding for α-tropomyosin, a structural thin filament
protein, have been found in autosomal dominant and recessive nemaline myopathies (TPM3) and in
familial cardiac hypertrophy (TPM1) 301-304. β-tropomyosin (TPM2) mutations cause autosomal
dominant NEM 305. Similarly, skeletal and cardiac α-actin is found mutated in NEM (AD / AR) and
FCH, respectively266,306. Mutation in troponinT has also been found to cause nemaline myopathy
268 and several nemaline myopathies with unknown genetic background still exist.
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7.4. Alterations in nuclear and cytosolic proteins
Emery-Dreifuss muscular dystrophies are early onset diseases with progressive weakness in
humeroperoneal muscles and cardiomyopathy 258. EMD was first described as an X-linked,
recessive disease, but later, also an autosomal dominant form was reported 307-310. The X-EMD
gene encodes for emerin, which is highly homologous to a lamina-associated protein, LAP2 311.
Emerin is localized to the inner nuclear membrane, together with lamin (encoded by Lamin A/C),
which is the protein mutated in AD-EMD 312. The primary roles of these two proteins is to stabilize
the nuclear membrane against mechanical stress during muscle contraction 313. Defects in calpain-3,
a cytosolic, muscle-specific enzyme, result in limb girdle muscular dystrophy 2A 314-316. Calpain-3
is a member of a family of calcium activated proteases and its interaction with several cytoskeletal
proteins have been reported 105. The mechanisms behind LGMD2A have been proposed to involve
nuclear apoptosis 317, muscle differentation 318 or process of membrane resealing and repair 319,320,
but the final mechanisms appear elusive.
Fukutin is a recently discovered protein, associated with Fukuyama congenital muscular dystrophy,
the most common autosomal recessive muscular disorder in Japan 321,322. It has been localized to
the extracellular matrix, but in vitro experiments have shown that it can also appear in the Golgi
complex and secretory granules 323. Furthermore, computer analysis of the fukutin sequence have
proposed it to be an enzyme that could modify cell surface glycoproteins 324. Thus, fukutin could
modify sugar residues of dystroglycan and other glycoproteins within the extracellular matrix and
fukutin mutations would lead into alterations of the ECM 258,324.
X-linked recessive myotubular myopathy (XLMTM) is a very severe congenital myopathy, which
is caused by mutations in the myotubularin gene 325. Myotubularin is a phosphatase that decreases
phosphatidylinositol 3-phosphate (PI3P) levels in cells by down-regulating phosphatidylinositol 3-
kinase (PI3K) activity or directly degrading phosphatidylinositol 3-phosphate. Deficiencies in the
myotubularin protein affect the PI3K and PI3P signalling pathway, which results in impairment of
muscle fiber maturation 325.
7.5. LGMD1A
Limb-girdle muscular dystrophy type 1A is an autosomal dominant disease characterized by
progressive weakness of the hip and shoulder girdle muscles together with a distinctive dysarthric
pattern of speech 261. LGMD1A is a rare, late onset disorder and currently, only one large,
extensively affected (62 patients) family of West Virginian origin, has been reported 261. By linkage
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analysis, the LGMD1A locus was originally mapped to chromosome 5q22.3-q31.3 326 and later it
was refined to a 7-cM region between markers IL9 and D5S178 327. The exact gene locus was
further narrowed down to an interval bounded by D5S479 and D5S594 and estimated to be 2 Mb in
size 328. At some point, anticipation was thought to be involved in LGMD1A, but it has not been
verified 329. The histopathological features of LGMD1A have not been reported.
7.6. Diagnosis and treatment of muscle diseases
As the genetic and molecular backgrounds of many muscular disorders have been explored, new
tools for diagnosis have become available. Thus, many recessive disorders can be characterized by
Western blot-analysis, using novel antibodies against altered muscle proteins. In dominant forms,
however, the alteration many times interferes with a special function of the affected protein and
does not change the size or amount of the protein. Accordingly, the diagnosis in these cases remains
more difficult than in recessive disorders. Currently, specific therapeutic treatment for inherited
diseases does not exist. Discovery of the genetic defects behind the muscular diseases and
understanding of their pathogenesis provides new tools for experimental treatment approaches. In
mice, isolated and cultured satellite cells have been already successfully injected into affected
muscles, where they differentiate to new myocytes and thus partially compensate for the loss of
muscular mass 330. This technique, together with targeted gene therapy, will undoubtedly be one of
the most widely studied possibilities in the future. Another appealing possibility could be
upregulation of compensating genes, like utrophin in dystrophin deficiencies 182,186,187.
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AIMS OF THE STUDY
The major aim of this study was to characterize the structure and function of myotilin, a novel
sarcomeric protein. This was pursued by attempting to:
• determine the primary structure of myotilin
• study the expression of myotilin in adult human tissues
• determine the structure and chromosomal localization of the myotilin gene
• identify the proteins that interact with myotilin
• study the expression and function of myotilin in skeletal muscle cells
• study putative associations of myotilin with muscle diseases
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                            MATERIALS AND METHODS
Cloning and sequencing of myotilin cDNA
A partial cDNA was used for screening of the full-length myotilin cDNA from a skeletal muscle
library. Positive clones were sequenced with an ABI 310 Genetic Analyzer. The coding region of
myotilin (full-length, wt) and partial fragments were amplified from the original 2245 bp library
clone. The PCR products were digested with restriction enzymes and ligated into different
expression vectors. Constructs and vectors, used in this study, are listed in table 2.
Table 2. Plasmids and vectors used in the study. Vector
Plasmids                  Description                                         Reference                    Used in
CT-GFP- Full-length myotilin in      Invitrogen III
MYOT-SIT pcDNA 3.1 vector with
green fluorescent protein tag
EG202-MT Full-length myotilin in   Guyris et al., I
bait  1993 331
EG202-R1R4 α-actinin spectrin-like I
repeats 1-4 in bait
Gex4T glutathione-S-transferase        Pharmacia I
Gex4T-ABD-R2 GST-tagged α-actinin     Kahana & I
from actin-binding domain      Gratzer,
to spectrin-like repeat 2 1991 332
Gex4T-R3-EF GST-tagged α-actinin -“  - I
from spectrin-like repeat 3
to the end
Gex4T-MT80-462 GST-tagged myotilin II
residues 80-462
JG4-5-MT Full-length myotilin in        Guyris et al., I
prey 1993 331
JG4-5- MT215-498 Myotilin 215-498 in I
prey
JG4-5-R1R4 α-actinin spectrin-like I
repeats 1-4 in prey
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pAHP-MT HA-tagged, full-length   Dr. Tomi II
 myotilin Mäkelä
pAHP- MT215-498 HA-tagged myotilin,  II
residues 215-498
pBK-MT Full-length myotilin in       Stratagene I
Bluescript vector
pBK-MT215-498 Myotilin 215-498 in -“  - I
Bluescript vector
pEGFP-α-actinin non-muscle -α-actinin Dr. Carol II, III
with green fluorescent Otey
protein tag
pET23-EEF pET-23a vector with Dr. Peter  III
inserted EEF tag + van der Ven
α-, β- and γ-filamin
constructs  
pET23-EEF- Myotilin Ig-domains  III
MYOT-I
pET23-T7 pET-23a vector with Dr. Peter III
inserted T7 tag + van der Ven
α- and γ-filamin
constructs
pGADPd empty prey vector Young et al.,  III
1998 111
pGADPd-MYOT- Full-length myotilin  III
SIT in prey
pGADPd-MYOT-S myotilin serine-rich  III
 domain in prey
pGADPd-MYOT-I Myotilin Ig-domains  III
 in prey
pKKtac-MT Full-length myotilin in           Dr. Kristiina  II
pKK vector under tac- Takkinen
promoter
pKKtac-MT116-498 Myotilin fragment 116-498 -“  - II
in pKKtac vector
pMYP-MYOT- Full-length myotilin in Dr. Peter II, III
SIT pCAT3 vector under van der Ven
myomesin promoter
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pMYP-MYOT-I Myotilin Ig-domains in Dr. Peter  II, III
pCAT3 vector under van der Ven
myomesin promoter
pMYP-MYOT-S myotilin serine-rich domain Dr. Peter  II, III
 in pCAT3 vector under van der Ven
myomesin promoter
pLexPd- γ -filamin Ig-domains Young et al., III
γ-fil d19-21 19-21 in bait 1998 111
pLexPd- γ -filamin Ig-domains  III
γ-fil 20-21 20-21 in bait
pSVβ-gal β-galactosidase cDNA,     Clontech II
transfection control
Production of myotilin antibody
A polyclonal antibody was raised in rabbits using a synthetic branched, lysine-cored 17 amino-acid
peptide of myotilin, corresponding to residues 353 – 369, as an antigen. The antibody was purified
on an affinity column using the corresponding single chain peptide coupled to CNBr-activated
Sepharose beads as the ligand. Other antibodies, used in this study, are listed in table 3.
Table 3. Antibodies used in the study.
Antibodies                                                   Reference                                            Used in
Actin (AC40) Sigma I
α-actinin BM 75.2 mAb Sigma III
α-actinin EA53 mAb Goncharova et al., 1992 333 II, III
α-actinin (67CB11) Närvänen et al., 1987 334 I
Anti-HA mAb (12CA5) Roche Diagnostics II
Filamin (RR90, α- and γ-filamin) van der Ven et al., 2000 126 III
Filamin (1680, α-filamin) Chemicon III
FITC-anti-mouse IgG Cappel research products I, II
FITC-anti-mouse IgG1 Rockland Inc. II, III
 LexA mAb Clontech III
Titin T11 Sigma I
Titin T12 mAb Fürst et al., 1988 335 II, III
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TRITC-anti-rabbit IgG Jackson Immunoresearch I, II
TRITC-anti-rabbit IgG2b Rockland Inc. II, III
T7-tag mAb Novagen II
X63 ATCC I
Y1/2 (EEF-tag) mAb Wehland et al., 1983 336 III
Structure and chromosomal localization of the myotilin gene
The organization of the myotilin gene was determined by comparing the myotilin cDNA with the
genomic sequence from chromosome 5 PAC clone 9c13. Furthermore, a commercial P1 clone was
used as a template for PCR amplification and sequencing of exon-intron boundaries using gene-
specific oligonucleotide primers.
The chromosomal localization of the myotilin gene was determined by radiation hybrid mapping
using the Genebridge II panel (Research Genetics). PCR primers, designed from the 3´-untranslated
region of myotilin cDNA, were used to amplify a 230 bp product from human genomic DNA. PCR
assays were performed as duplicates and the resulting data vector was analysed on the Whitehead
Genome Center server.
mRNA and protein studies
Northern blot analyses were performed with commercial multiple tissue mRNA filters, except the
blot from differentiated human skeletal muscle cells, which was prepared as follows: frozen human
skeletal muscle cells from liquid nitrogen were quickly thawed, plated and grown in DME medium
supplemented with FCS, Ultroser G and antibiotics. Differentiation was induced by changing the
cells to a low-nutrient  culture medium. Cells were grown on 60 mm plates, differentiated 0-6 days
and subjected to mRNA isolation. Five µgs of each mRNA were mixed with RNA gel buffer and
incubated at +65 o C for 15 min. Samples were run in a formaldehyde-agarose gel and transferred to
nitrocellulose membrane. 32P-labelled full-length myotilin cDNA or a 320 bp cDNA fragment,
encoding amino acids 369-471, were used as probes in the hybridizations. Rat GAPDH cDNA was
used as a loading control in the hybridization of the differentation samples.
In vitro translation experiments were performed with a coupled reticulocyte lysate kit (Promega)
using 35S-labelled methionine for detection. For western blotting, fresh tissues or cultured cells were
homogenized in reducing Laemmli buffer. Equal amounts of protein, as estimated by Coomassie
staining, were separated in SDS-PAGE and transferred to nitrocellulose filters, which were
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subsequently probed with different antibodies and detected with enhanced chemiluminescence
(ECL).
Recombinant protein expression and purification
Full-length coding region and partial fragments of myotilin cDNA in different expression vectors
were transformed into BL21 (Plys-S or DE3) cells. Protein expressions were induced with 0.5 mM
IPTG for 2 hours at room temperature. The His-tagged fusion proteins were purified with nickel-
Sepharose and the GST fusion proteins were purified using glutathione-Sepharose beads. The
purified proteins were stored in 20 mM Tris, 50 mM NaCl, pH 8.
Actin filament cosedimentation, bundling and stabilization assays
For both co-sedimentation and bundling assays, actin filaments were assembled from purified rabbit
muscle actin and incubated 30 min. at +25 o C. Variable amounts of myotilin polypeptides (GST- or
His-tagged) or control proteins were added to preassembled filaments.  Reactions were incubated 30
minutes at +25 o C and centrifuged either 100 000 x g, 1h in a Beckman ultracentrifuge (co-
sedimentation) or 14 000 x g, 3 min. in an Eppendorf centrifuge (bundling assay). Pellets and
supernatants were separated and their volumes were equalized with Laemmli buffer. Samples were
subjected to SDS-PAGE and proteins were visualized with Coomassie staining and quantitated with
a densitometer. For fluorometric measurement of F-actin disassembly, purified, pyrene-labelled
actin and unlabelled actin were used. Preassembled  filaments and different amounts of GST- or
His-tagged myotilin were incubated for 30 min. at +25 o C. Subsequently, 2 µls of 500 µM
Latrunculin B was mixed with each reaction at time and  the actin filament disassembly was
monitored by decrease in pyrene fluorescence.
Transient expression of full-length myotilin and myotilin domains
Cell lines used in this study are listed in table 4. Cells were seeded a day before transfections and
grown on glass coverslips to 30-40 % confluency, except C2C12 cells, which were grown on glass
coverslips for only 6 hours before transfection. Culture medium for C2C12 cells contained DMEM
supplemented with 15 % FCS and antibiotics, whereas other cells were grown in DMEM, that
contained 10 % FCS. All cells were transfected with Fugene according to the manufacturer´s
instructions, except that with C2C12 cells, 5 µgs of plasmid DNA and 6 µls of Fugene were used
per 35 mm well of cells. Transfected C2C12 cells were allowed to differentiate by changing the
cells to a low nutrient medium 24 h after the transfection. For immunofluoresence microscopy, the
43
cells were fixed with 3 % paraformaldehyde, permeabilized with 0.1 % Triton X-100-based buffer.
The cells were incubated with primary antibodies (3), followed by rhodamine- or fluorescein-
labelled secondary antibodies.
Table 4. Cell lines used in the study.
Cell lines                  Description                                        Reference                   Used in
COS-7 African green monkey ATCC II
kidney cells
CHO Chinase hamster ovarian ATCC II
Cells
C2C12 Mouse skeletal muscle ECACC II, III
Cells
HSkM Human skeletal muscle van der Ven  II
cells et al., 1993 337
NRC Neonatal rat Komiyama II
cardiomyocytes et al., 1996 338
Ptk2 Potoroo tridactylis ECACC II
kidney cells
Immunostaining of healthy adult tissues and cells and diseased human muscles
Bundles of bovine and human myofibrils were isolated, cytocentrifuged onto objective slides, fixed
in   –20 o C methanol and immunostained with various antibodies (I), followed by incubation with
rhodamine- and fluorescein-labelled secondary antibodies. Human skeletal muscle cells,
differentiated from one day up to six days, were fixed in 3 % PFA, permeabilized with 0.1 % Triton
X-100-based buffer and reacted with myotilin and titin (T12) antibodies (II), followed by incubation
with rhodamine- and fluorescein-labelled secondary antibodies. For immunohisto-chemical
staining, frozen sections of healthy and diseased human skeletal muscles were immobilized on
glass-slides and fixed in cold acetone. Muscle sections were stained with myotilin antibody or the
corresponding pre-immune serum as a control. Antibodies were detected with Elite Vectastain ABC
kit and the slides were counterstained with haematoxylin and eosin.
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Yeast two-hybrid analysis and in vitro binding assays
γ-filamin and α-actinin constructs in bait vectors were co-transformed into yeast cells with human
skeletal muscle cDNA library. Transformed cells were grown on selection plates according to Trafo
or Matchmaker protocols (I, III, IV). After 5 days at 30 o C, colonies were screened for activity of
the LacZ reporter gene either in filter assay or on LacZ plates. Positive clones were purified and
transferred to E. coli, where the plasmids were amplified for further cDNA purification and
sequencing. For mapping the interaction regions between myotilin and γ-filamin or myotilin and α-
actinin, distinct portions of individual proteins were cloned into pGAD10AD and pLexA vectors
(see table I),  cotransformed into L40 or BOY 1 yeast cells and plated on selection plates. Positive
clones were grown in selective medium and for analysis of fusion proteins, 1 ml of overnight
culture was boiled and analysed by SDS-PAGE and immunoblotting. Interactions were confirmed
by the β-galactosidase activity assay.
In in vitro binding assay, purified GST-α-actinin fusion proteins, bound to glutathione Sepharose
beads, were incubated with 35S-labelled, in vitro translated full-length myotilin. After washings, the
bound material was eluted with Laemmli buffer, subjected to SDS-PAGE and detected by
immunoblotting.
Immunoprecipitation
For co-immunoprecipitation experiments, purified myotilin and γ-filamin polypeptides were used.
Anti-EEF or anti-T7 antibody was added to the protein of interest, incubated with shaking for 60
minutes at 4 oC. Subsequently, protein G Sepharose beads were added to the mixture and incubation
was continued for additional 30 min. After washing the beads three times, the Sepharose-bound
complexes were sedimented twice through a sucrose cushion. Beads were further washed and bound
material was eluted from the beads with Laemmli buffer. Proteins were separated by SDS-PAGE
and blotted to nylon membrane and the precipitated proteins were identified with corresponding
antibodies (III). Coimmunoprecipitation from yeast cells was performed as follows: yeast cells,
expressing both HA-tagged myotilin and LexA-γ-filamin, were lysed and the supernatant was
separated from the cell remainders. Either HA- or LexA-antibody was added to the yeast cell lysate
and incubated with shaking for four hours at 4 o C. Subsequently, protein G sepharose beads were
added and the incubation was continued for 30 minutes. After washing, bound proteins were eluted
from the beads and subjected to SDS-PAGE and immunoblotting as described above.
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Cell fractionation
Samples of cultured cells or adult human tissues were homogenized with a Dounce homogenizer in
ice cold buffer I (10 mM Tris, pH 7.5 and 2 mM PMSF with protease inhibitor cocktail). After 10
minutes of incubation on ice, buffer II (10 mM Tris, pH 7.5, 20 % sucrose, 0.3 M KCl, 2 mM
PMSF and protease inhibitors) was added to the solution and centrifuged at 12 000 g at 4 o C for 3
min. The pellet contained mainly cell cytoskeleton and nuclei. The supernatant was centrifuged at
105 000 g for 1 hour at 4 o C. The final pellet contained the cell membranes and the supernatant
represented the cytosolic fraction of the cells.
Electron microscopy
Bundled actin filaments were applied to formvar-carbon coated nickel grids and negatively stained
with 1% uranyl acetate. The grids were air-dried and observed with a JEOL 1200 EX transmission
electron microscope. The electron micrographs were digitized on a flat-bed scanner and measured
by NIH image 1.62.  For immunoelectron microscopy, human skeletal muscle tissues were fixed in
a solution of 4 % PFA and 1 % glutaraldehyde with Hepes buffer, pH 7.5. Subsequently, samples
were washed with the same buffer, dehydrated with series of ethanol and embedded in LR White.
Ultra thin sections were rinsed floating on washing buffer for 10 min., etched for 15 min. with
saturated sodium metaperiodate, followed by a rinse in water and 10 minutes in 0.1 M HCl. Grids
were rinsed with water and preincubated with 5 % normal goat serum for 35 min. in room
temperature. Overnight incubation with the primary antibody was followed by secondary antibody,
coupled to colloidal gold. After washing, samples were postfixed with 1 % glutaraldehyde and
examined with a Zeiss 900 electron microscope.
SSCP analysis
To detect the C450 to T mutation, a 279 bp fragment of myotilin exon II was amplified by PCR
using genomic DNA, isolated from affected individuals and healthy controls. The amplified
samples were denatured for 3 minutes at 94 o C and chilled on ice for 5 min. Samples were run on
MDE gels (IV) and detected by silver staining.
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                             RESULTS AND DISCUSSION
Structure of myotilin and homology with other intracellular Ig-family proteins (I)
A 200 bp cDNA sequence, encoding for a novel protein, was identified by a yeast two-hybrid
screening using α-actinin as a probe and by EST database analysis. This sequence was further used
to screen human muscle cDNA library, which resulted in identification of a full-length cDNA,
containing 2245 bp sequence with an open reading frame of 1494 bp (bp 280 – 1774). It encodes for
a 498 amino acid polypeptide, which was termed myotilin. The unique NH2-terminal part of
myotilin is particularly rich in serine residues and it contains a short hydrophobic portion (residues
57-79). The COOH-terminus contains two immunoglobulin-like domains, 90 residues each,
involving amino acids 252-341 and 351-441. Structurally they are composed of  seven β-sheets and
thus fall into the category of C2-type Ig-folds. This intracellular type of Ig-domain is found mainly
in sarcomeric proteins like titin, γ-filamin, myomesin, M-protein and MyBP-C 78,92,102, although
proteins like palladin and trio 339,340 in non-muscle cells, contain the same type of Ig-domains. By
sequence comparison, the Ig-domains of myotilin are most homologous to Ig-domains 2 and 3 of
palladin and N-terminal domains 7 and 8 of titin 339,341. Like myotilin, palladin contains a serine-
rich N-terminus, but the C-terminus includes three C2 Ig-domains. Thus, palladin can be
structurally regarded as a smooth muscle and non-muscle homologue of myotilin and together they
form a novel family of actin-associated proteins 339,341. Additionally, the extreme N-terminus of
palladin contains a polyproline stretch, which is not present in myotilin. The FPPPP-motif of
palladin is homologous to Ena/VASP-family proteins, which interact with profilin via the
polyproline stretch 342,343. Profilins, on the other hand, participate in actin filament dynamics 1 and
thus the role of palladin most probably differs from that of myotilin. Recently, a novel muscle
protein, myopalladin, was identified 127. It contains five Ig-domains, which are highly homologous
to Ig-domains of palladin and myotilin and thus it could represent a third member of this protein
family.
After the identification of myotilin by us was published, Godley and her coworkers independently
described a novel protein with titin-like features and named the corresponding gene TTID 344. The
gene was found during positional cloning of a myeloid tumor suppressor gene in chromosome 5q.
The gene is identical to myotilin and most of their structural data is identical to ours with the
exception of the Ig-domain predictions. They found two internal repeats of 43 amino acids
homologous to N-terminal Ig-domains of titin. However, the structure of intracellular Ig-domains
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involves 90 - 95 residues 345 and thus the repeats Godley and coworkers found, would correspond
only to half of an Ig-domain each.
Mouse myotilin is composed of 496 residues instead of 498 in the human orthologue (IV). The
protein is highly conserved between the two species:  89 % of the residues are identical and 93 %
similar.
Organization and chromosomal localization of the myotilin gene (I)
The myotilin gene is composed of 10 exons with the translation initiation signal in exon II. Thus, the
small 69 bp exon I, together with the beginning of exon II, forms the 5´-untranslated region of the
mRNA. The Ig-domains of myotilin are encoded from exons VI, VII (Ig-domain I), VIII and IX
(domain II). In additional cDNA library screenings, shorter cDNA clones were found with alternative
splicing in exon II (unpublished results). The size of these cDNAs corresponds to the smaller 2.2 kb
transcript detected in northern blot analysis. In these splice variants, the 5´-splice site is the same
(starting at bp 105 in the cDNA), but in one case, the 3´splice sites follows the normal exon-intron
junction (bp 636) and in the other, it is in the middle of exon II (bp 505). In in vitro translation, these
splicings result in protein products of 42 and 35 kD, respectively (more detailed discussion below). In
the 35 kD variant, the absence of the whole 3´-end of exon II abolishes the binding site for α-actinin
and would thus lead to a polypeptide with a different role from the full-length one.
The genomic structure of the Ig-domains reveals similarities with other known Ig-family members,
especially with myomesin and M-protein genes, in which the Ig-like domains are also encoded by
two exons flanked by a phase I intron 346. The myotilin gene is relatively small, less than 20 000 bp,
and the proportion of the coding sequence within the gene is 11 %. The intracellular Ig superfamily
genes show striking differencies in their compactness. For titin, the percentage of open reading frame
is extremely high, 67 %, whereas for γ-filamin it is 30.5 %, 21 % for MyBP-C and 5 and 7 % for
myomesin and M-protein, respectively 347-350. This indicates that the Ig superfamily members have
diverged rather early in evolution and developed independently. Gene predictions from chromosome
5 Pac-clone (9c13) have revealed a putative promoter area immediately upstream from the first exon,
with a  TATA-box at position -38 and two MyoD / Myf 5 binding sites at -61 and -78 (unpublished
results).
Chromosomal localization of the myotilin gene by radiation hybrid mapping located the myotilin
gene on chromosome 5q31 between markers AFM350yb1 and D5S500. This locus is inside the 2 Mb
region, that has been reported to contain an unknown disease gene causing LGMD1A 328. Another
dominant muscular disease, vocal cord and pharyngeal weakness with distal muscular dystrophy,
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(VPDMD) was also mapped to a larger, but overlapping interval in 5q31 (between markers D5S458
and D5S1972) 351 proposing an association between myotilin and these muscular dystrophies.
Expression of myotilin in adult and fetal tissues  (I)
By northern blot analysis, two different transcripts (2.2 and 2.5 kb) have been detected with the
strongest expression in adult, human skeletal and cardiac muscles. Hybridization of additional
commercial multiple tissue filters and a dot blot filter have revealed minor expression also in
prostate, colon, small intestine, esophagus, salivary and thyroid  glands, bone marrow and K562
cells (data not shown). This is in agreement with the expression data of Godley and coworkers 344.
Interestingly, in heart and prostate, the 2.5 kb transcript is more prominent than the 2.2 kb, whereas
in the colon and small intestine, only the 2.2 kb transcript is present.
A polyclonal antibody, raised against a synthetic myotilin peptide (residues 353 – 369), revealed a
prominent 57 kD protein band in western blotting from skeletal muscles. An identical size
polypeptide was obtained by in vitro translation from the original cDNA clone. Other tissues have
shown different band patterns with the antibody, composed of  35, 42, 57 and 75 kD bands.
Additionally, a 100 kD band, representing the size of a dimer, has been detected. Separation of
membraneous, cytoskeletal and cytosolic fractions reveals the presence of all these bands also in
skeletal muscles.
Figure 7. Western blotting of human
tissue lysates. 1. total lysate from heart,
2. total lysate from skeletal muscle,
3. insoluble  and 4. soluble fraction of
skeletal muscle, 5. insoluble and
6. soluble fraction from HeLa-cells
However, the high abundancy of the 57 kD protein dominates the muscle lysates. The open reading
frame of the smaller splice variants encode for 35 and 42 kD proteins and in vitro translations have
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produced proteins of equal sizes (data not shown). Thus, the three smallest protein bands may result
from alternative splicing of the myotilin gene. The identity of the 75 kD band is still unknown. Our
further library searches and the 5´-race experiments performed by Godley et al. 344 have not led to
identification of additional sequences upstream of the current 5´-end. Interestingly, this isoform
together with the 35 kD protein, is soluble in non-ionic detergents, whereas the 42 and 57 kD
proteins are insoluble (Figure 7). Furthermore, in cell fractionations, the 75 kD isoform appears
only in the membrane fraction and the 57 kD protein is restricted to the cytoskeletal fraction. Most
strikingly, the most prominent isoform in cardiac muscle is the 75 kD protein with almost non-
detectable amounts of the 57 kD protein in the cytoskeletal fraction (data not shown). One possible
explanation could be post-translational modification of the 57 kD protein, which could affect both
the size and cellular localization of the protein. Glycosylation of intracellular proteins has been
reported 352. However, deglycosylation of tissue lysates with O-glycosidase or N-glycosidase had
no impact on myotilin isoforms (data not shown) and therefore it is unlikely, that this form of
modification could explain the presence of the 75 kD band. Myotilin has several putative
phosphorylation sites in its N-terminus, although that would most probably not explain the large
size difference. Addition of lipids (acylation or farnesylation) is also a putative important
modification and interestingly, farnesylation of ornithine decarboxylase (ODC) and Ki-ras have
been reported to translocate both proteins to the cell membrane 353,354. Diversity in protein isoforms
between cardiac and skeletal muscles have been reported (titin) 117,355 and both sarcolemmal and
sarcomeric appearance for a single protein has been detected, for instance in γ-filamin 126,157,158.
To reveal the exact locations and roles of each isoform, specific antibodies and RT-PCR based
studies will be needed.
Expression of myotilin during fetal development, studied by in situ hybridization and
immunohistochemical staining, reveals  myotilin expression initially in heart at embryonic day 9,
followed by expression in somites and neuroepithelium at E10 356. At E13, myotilin expression
reaches its peak and it is found in a variety of tissues, including the nervous system, lung, liver,
digestive tract and kidney. However, during organ differentiation, myotilin expression is down-
regulated in analogy with some other cytoskeleton associated proteins, such as β-dystroglycan and
palladin 339,357. At E16, myotilin synthesis is restricted mainly to striated muscles and peripheral
nerves, with a weak expression in bronchial epithelium, thyroid and parathyroid glands, digestive
tract and liver. These results suggest, that myotilin could have a role in tissue modelling during
organogenesis. However, somitic expression of myotilin appears delayed in comparison to other
sarcomeric proteins, which are usually detected at E9 96. This suggests, that in skeletal muscles,
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myotilin is involved in later events of myofibrillogenesis, like myofibril alignment 358.
Immunohistochemical staining of human embryos has revealed similar results indicating that
transcriptional regulation of human and mouse myotilin is conserved. Also the expression data from
immunostainings of adult human tissues supports the findings from later developmental stages. The
main location for myotilin in adult tissues is in striated muscles and peripheral nerves (I), although
weaker expression is found in thyroid gland, colon and certain blood cells (data not shown).
Futhermore, in muscles, both sarcomeric and sarcolemmal staining have been detected.
Protein interactions of myotilin (I, II, III)
Identification of putative binding partners and individual binding sites is an important step in
exploring the function of a novel protein. Yeast two hybrid analysis with full-length myotilin and a
COOH-terminal fragment (215-498) showed that myotilin is capable to dimerize (I). The result was
further verified with a cross-linking assay using a chemical cross-linker, EGS (ethylene-glycolbis-
succinimidylsuccinate, II). A COOH-terminal myotilin fragment (116-498), appears already without
the cross-linker in two forms, but addition of the chemical cross-linker turns the balance towards the
dimer form and the monomer disappears. These results indicate that myotilin can form homotypic
interactions and it involves either one or both of the Ig-domains or the flanking regions.
Full-length myotilin and a smaller myotilin fragment (residues 80-462) were found to bind muscle
F-actin with stoichiometry of 1:1 (one myotilin molecule bound to one actin monomer). The actin-
binding site in myotilin involves the Ig-domain area, which most probably is also responsible for
the dimerization of the molecule. In proteins like α-actinin and dystrophin, the dimerization occurs
via the central spectrin-like repeats, whereas ABP 120 and filamins have shown, that also an Ig-
domain can account for the dimerization interface 151,156. The most attempting scenario is that the
function of individual Ig-domains is diverged in myotilin. The highest homology of the Ig-domains
is seen between domain 1 of myotilin and N-terminal domain 7 of titin. As this particular titin
domain is known to bind actin at the edge of the Z-disc 16, the first Ig-domain of myotilin could
encounter the same function. Thus the dimerization could occur via the second Ig-domain and, if it
happens in an antiparallel fashion, it would separate the actin-binding domains to opposite
directions.
Originally, the interaction of myotilin with α-actinin was discovered between the N-terminal half of
myotilin and the spectrin-like repeats R3-R4 of chicken gizzard smooth muscle α-actinin. The yeast
two-hybrid result has been verified with an in vitro-binding assay using recombinant α-actinin
fragments and in vitro translated, 35S-labelled myotilin. However, more recent studies with human
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α-actinin constructs have refined the binding sites. The binding site for human α-actinin-2 resides
between N-terminal residues 80 – 125 of myotilin and the myotilin-binding site in α-actinin-2 is in
the second CaM-domain (EF3/4) of the C-terminal EF-hand (A. Taivainen, unpublished results).
Whether the results indicate a species difference or difference in α-actinin isoforms, is not known.
Structural analysis has demonstrated that the EF-hand structure differs between non-muscle and
muscle isoforms 137-139 suggesting also functional differencies. In muscle cells, myotilin is
competing for the C-terminal binding-site of α-actinin-2 with two other Z-disc proteins, titin and
ZASP 111,128,145,146, but whether the binding sites overlap, is not known. However, expression
studies with truncated α-actinin constructs have shown that the extreme C-terminus is functionally
very important for integrity of the sarcomere, especially the Z-line 147,148 and thus proteins binding
to this site are of great interest. In myotilin-α-actinin double transfected cells, interaction with
myotilin redistributes α-actinin from the cell periphery into the prominent actin cables. This
indicates that the interaction between these proteins is of sufficient affinity to compete with the pre-
existing localization determining interactions.
The interaction between myotilin and the muscle-specific isoform of filamin, γ- filamin /ABP-L,
was also discovered through a yeast two-hybrid search. A unique insertion in Ig-domain 20 was
shown to target γ- filamin to Z-disc via interaction with Ig-domains of myotilin (III). A minor
fraction of γ- filamin has been found to bind  γ- and δ-sarcoglycans at the sarcolemma 158.
Identically, myotilin has also been found both at the myofibrillar Z-disc and the sarcolemma, which
may be an indication of a joint function for these proteins in both locations. During
myofibrillogenesis, filamin first appears in stress fiber-like structures, then it disappears for several
days and finally reappears at the periphery of Z-disc 359,360. In developing cardiac muscles, γ-
filamin can be detected only from the 14 somite stage onwards, when the heart is already beating
361, whereas myotilin is found already at day 9 in mouse embryos. Thus, the presence of myotilin in
the Z-disc could be prerequisite for the final myofibrillar location of γ- filamin. However, coupled
expression of myotilin and the small muscle-specific insertion of γ-filamin in non-muscle cells led
to relocation of myotilin from actin cables to large  protein aggregates, composed of these two
polypeptides, suggesting that the insertion in γ-filamin might be sufficient to target myotilin to the
Z-disc. Conversely, the interaction between myotilin and α-actinin is also strong and as α-actinin is
located already into the primordia of the Z-discs, one could expect α-actinin to be the guiding
molecule for the location of myotilin. Taken together, γ-filamin most probably participates in the
early organization of actin cytoskeleton during the first stages of differentiation 126 but its final
location in the Z-disc might be dependent on the presence of myotilin.
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Expression of  endogenous myotilin in differentiating muscle cells (II)
The role of myotilin in myofibrillogenesis was studied using isolated human skeletal muscle cells,
differentiated from one up to six days. Northern blotting results indicate that the expression of
myotilin mRNA starts at day three in cell culture and higher amounts are seen after day 4. Faint
protein expression can be seen from day 2, but the prominent 57 kD band comes on day 6. Most of
the thin filament proteins are expressed at the very beginning of differentiation, which is an
indication of their involvement in early sarcomeric organization 235,254. Only tropomodulin appears
a little later to the pointed ends, probably guided by nebulin 50,51. Some proteins, like γ-filamin and
FATZ, are present also in non-differentiated cells and their expression levels are upregulated in the
beginning of differentiation 129,362. Both the cell differentiation studies and the fetal expression
patterns support the idea, that myotilin is expressed at the time, when myofibrils are aligned
towards rigid sarcomeric structures. The strictly controlled, late appearance of myotilin suggests
that myotilin has a unique role in myofibrillogenesis, most probably involved in myofibril
reorganization.
F-actin cross-linking and stabilization (II)
The fact that myotilin binds F-actin inspired us to look for other putative effects that myotilin could
have on actin filament assembly. Subsequently, we found that myotilin cross-linked actin filaments
in vitro into large, stable bundles. It is obvious, that actin cross-linkers with only one actin-binding
site have to form dimers via different modular structures 13. The efficient cross-linking ability of α-
actinin results from a rod-like structure of the dimerized protein, where the actin-binding sites
reside in both ends of the molecule 136. Other proteins of the family (dystrophin and spectrin) are
composed of the same structural motifs as α-actinin, but they differ in the number of central
spectrin-like repeats, resulting in differences in the actin filament assemblies 134. Thus the length of
the spacer between actin-binding domains determines the spacings between actin filaments. In
bundles, cross-linked with α-actinin, the width of the spacer has been observed to be 36-38 nm 363.
In thin filament reconstructions, however, the spacings have been found to be only 18 nm,
indicating that other factors, in addition to α-actinin, modulate the connections between thin
filaments 123. The length of a spectrin-like repeat is approximately 50 Å and thus the distance
between the actin-binding domains in α-actinin is more than 200 Å 13. An Ig-domain, on the other
hand, is only 20 Å in length and thus the spacer between ABDs in a myotilin dimer would be less
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than 50 Å, suggesting that myotilin would cross-link filaments into extremely tight bundles 13.
However, the electron microscopic analysis of the cross-linked bundles showed that myotilin
created more loosely packed bundles than α-actinin suggesting that the localization and orientation
of these proteins between the filaments is different. The presence of both cross-linkers in the actin
bundles turned them into large, uniform, tightly packed cables. This indicates that either myotilin
has an additive effect on the bundles, cross-linked by α-actinin, or they form a terniary complex,
which contributes to the spacing of thin filaments.
In order to establish the in vivo function of myotilin, COS-1, CHO and mouse skeletal muscle cells,
C2C12, were transfected with myotilin constructs. In non-muscle cells, N-terminal fragments of the
protein locate either diffusely or along stress fiber-like structures, most probably driven by the α-
actinin binding site (data not shown). C-terminal fragments, on the other hand, co-localize with the
cortical actin cytoskeleton.  This is consistent with the presence of the actin binding site in the C-
terminal half. Full-length myotilin co-localizes with actin, like the C-terminus but additionally, it
induces formation of prominent actin cables inside the cells. The actin bundling effect is unique
among sarcomeric proteins. Not even α-actinin, which has been thought to be the major protein
responsible for thin filament cross-linking, can produce a similar phenotype in vivo 364,365.
However, expression of an actin bundling protein espin and its Drosophila homologue, forked, in
COS-1, CHO  and C2C12 cells have been found to cause formation of large, rigid actin fiber
bundles resembling those induced by myotilin 366,367. Espins are major actin-bundling proteins of
sertoli cell - spermatid ectoplasmic junction, whereas forked protein functions in the Drosophila
bristle formation. Both proteins efficiently cross-link parallel actin filaments, whereas proteins like
α-actinin and γ-filamin cross-link filaments of opposing polarity. Whether myotilin cross-links
parallel or antiparallel filaments is not known. However, it has been proposed, that within the Z-
disc, both parallel and antiparallel cross-links would appear 19. Both espins and forked are
extremely insoluble proteins, like myotilin, although structurally these proteins appear very
different. The reason for the insolubility is not known, although in myotilin it could result from the
high amount of hydrophobic residues.
Previously, the high kinetic stability of cross-linked actin filaments have been thought to result from
a simple steric hindrance of the cross-linkers, which lowers the dissociation rate of F-actin 13.
However, a cross-linker can also prevent actin filament disassembly independently from the cross-
linking event 368. Our in vitro experiments with Latrunculin A showed that myotilin is an efficient
F-actin stabilizer. Moreover, the resistance of large actin cables, induced by expression of myotilin
in cultured cells, to Latrunculin A treatment showed that the impact of myotilin on F-actin assembly
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can be considered extremely strong and irreversible. Taken together, myotilin is a very potent actin
cross-linking protein in vitro and in vivo.
The effect of myotilin  on myofibril assembly (II, III)
 As discussed above, transient expression of myotilin in non-muscle cells leads to reorganization of
the whole actin cytoskeleton. In muscle cells, the same expression constructs, containing an
constitutively active CMV-promoter, caused similar actin cable formation, which was deleterious
for myocyte differentiation. Following the discovery, that expression of endogenous myotilin was a
late event in comparison to other thin filament proteins, we began to search for tools to delay the
transient expression in differentiating myotubes. One option was to use the myomesin promoter in
the expression constructs as myomesin is also expressed at later stages of development 252,369,370.
Using the myomesin promoter, very little, if any myotilin protein was seen in filament-like
structures before it appeared in the developing and mature Z-discs without obviously disturbing
myofibril assembly. However, expression of truncated myotilin fragments under the same
myomesin promoter led to drastic effects on myofibrillar assembly. Neither N- nor C-terminal
fragments show clear cytotoxic effects in the beginning of the differentiation. However, when the
differentiation proceeds, expressed polypeptides, together with other myofibrillar proteins, begin to
accumulate, which results in severe disruption of myofibrils. This indicates, that complete myotilin
protein, with the α-actinin binding site in the N-terminus and the γ-filamin and actin binding sites in
the C-terminus, is required for proper myofibril formation. Many of the sarcomeric proteins, for
example titin and α-actinin, have a similar impact on myofibril assembly, when important protein
interaction modules have been deleted 147,148,371.  This highlights the importance of a proper
interplay of several structural proteins in the sarcomeric organization 13,20.
The role of myotilin in Z-disc formation  (II)
Immunoelectron microscopical studies confirmed that myotilin is a bona fide component of the Z-
disc. Other known Ig-family proteins in the Z-disc are γ-filamin and the N-terminus of titin 102,126.
Ig-modules have been found as one of the main structures responsible for sarcomeric integrity 73
and, for example, the anchorage of thick filaments in the M-line is regulated by Ig-family proteins
titin, myomesin and M-protein 21,372. Thus it is tempting to speculate that titin, γ-filamin and
myotilin, together with α-actinin, could encounter the same function in the thin filament anchorage
at the Z-disc. In fact, via interactions with α-actinin and γ-filamin, myotilin brings together three
efficient actin filament cross-linkers at the Z-disc, making it a unique complex in actin assemblies.
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Interactions between titin Z-repeats and the C-lobe of α-actinin-2 have been considered responsible
for the cross-connections between thin filaments in the Z-disc, thus determining the width of the Z-
disc 132,145,146. Expression of truncated α-actinin, lacking the extreme C-terminus, has been shown
to result in Z-disc hypertrophy and induction of nemaline bodies 147,148. These findings have been
largely explained by the importance of titin-α-actinin interactions in the Z-disc assembly 132,150.
However, expression of truncated myotilin, lacking the N-terminus, including the α-actinin binding
site, resulted in dramatic effect on myofibril assembly (II, III). At first, myotubes expressing the C-
terminal part of myotilin, showed targeting of the recombinant polypeptide to immature Z-discs, but
later the myofibrillar proteins formed filamentous bundles or aggregates and proper myofibrils were
never observed. Thus, it is possible that the interaction between myotilin and α-actinin plays a key
role in Z-disc assembly. Considering the characteristics of myotilin, i.e. strong actin cross-linking
and stabilizing activity, interactions with key structural components of the Z-disc and precisely
regulated temporal expression, one may envisage a role for myotilin in forming a “final lock” that
provides rigidity and stability to the Z-disc structure (Figure 8).
    Figure 8. Schematic representation of the Z-disc structure. The exact location for γ-filamin
    could not be defined by current information.
Association of myotilin with LGMD1A (IV)
Since chromosomal mapping results identified myotilin as a candidate gene to LGMD1A and
VPDMD, further studies were undertaken. To test whether myotilin is mutated in LGMD1A or
VPDMD, we used SSCP analysis and direct sequencing of myotilin exons. Both affected and
healthy members of the families were studied, in addition to control samples and samples from
patients with other muscular defects. In the VPDMD family, the known open reading frame of
myotilin and the exon / intron splice sites were not altered. On the other hand, in the LGMD1A
family, a single point mutation, C450T, was identified in the myotilin gene from affected
individuals only. This missense mutation results in the conversion of threonine 57 to isoleucine,
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which does not affect the size or expression level of the protein. By SSCP analysis, all affected
members and eight clinically asymptomatic individuals were found to carry the disease-associated
haplotype. However, these unaffected individuals were below the average age of disease onset (27.1
+ 8.5 years) and most probably will become symptomatic in further evaluations. Denaturing high
performance liquid chromatography (DHPLC) from the product of the mutant alleles revealed that
these transcripts are translated into protein. The mutation was not found to affect the α-actinin
binding site in myotilin. Interestingly, a drastic increase in the 75 kD myotilin isoform is observed
by western blotting, in comparison to the normal sample. LGMDs have been traditionally regarded
as diseases of the sarcolemma and, as the genetic backgrounds behind many diseases have been
established, defects in the sarcolemma-sarcomere connection has been found causative for LGMD
type diseases 259. Thus the sarcolemmal form of myotilin is of great interest when the molecular
mechanism behind the LGMD1A is explored. However, also pure sarcomeric proteins have been
found to cause LGMD type disease 298. Autosomal recessive forms of muscular diseases often
result in loss of expression of the affected protein, whereas in autosomal dominant forms, the defect
usually affects a functionally important module of the protein. This is in agreement with the
relatively normal expression of myotilin in the diseased muscles of LGMD1A patients. In affected
muscles of LGMD1A patients,  extensive myofibrillar disorganization and streaming of the Z-line,
similar to that seen in nemaline myopathy, have been detected. Nemaline myopathy, although it is a
clinically different disease from LGMDs, exhibits similarities with LGMD1A. In both diseases,
nemaline-like bodies appear inside the muscle fibers, containing mainly Z-disc proteins actin and α-
actinin 264. Recently, immunohistochemical analysis has revealed also myotilin as one of the
constituents of the nemaline rods (R. Schröder & P.Salmikangas, unpublished results). Thus far,
mutations in actin, troponin T, tropomyosin and nebulin have been associated with nemaline
myopathy 265-268 whereas mutations in α-actinin or myotilin have not been detected (K. Pelin, K,
Donner, unpublished results). The different clinical phenotype of the patients with nemaline
myopathy and LGMD1A suggest, that the Z-line streaming and appearance of nemaline rods in
LGMD1A might not be the primary cause of the disease, but rather secondary effects of the disease.
However, the Z-line streaming of the diseased muscle could also be a primary cause, resulting from
the failure of myotilin to stabilize the structure of the Z-disc. Taken together, identification and
characterization of myotilin has provided new tools for future diagnostics and therapies of
LGMD1A.
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                     CONCLUSIONS AND FUTURE PROSPECTS
This study describes the identification and characterization of myotilin, a novel thin filament
protein. It is a 57 kDa protein, that consists of two C2-type Ig-like domains flanked by a unique
serine-rich amino-terminus and a short carboxy-terminal tail. Myotilin binds F-actin and efficiently
cross-links actin filaments into prominent cables both in vitro and in vivo. Myotilin also decreases
the rate of F-actin depolymerization, which suggests that myotilin plays a role in thin filament
stabilization. The structural basis for the cross-linking activity is based on myotilin´s capability to
dimerize via its C-terminal half. In striated muscles, myotilin localizes to the Z-disc, where thin
filaments of opposing sarcomeres are cross-connected by α-actinin. Myotilin binds α-actinin and γ-
filamin, which both are important structural proteins of the Z-disc. Furthermore, myotilin enhances
the affinity of α-actinin for actin filaments, which increases the size and rigidity of in vitro cross-
linked actin bundles. The functional significance of the myotilin - γ-filamin interaction is less well
understood. γ-filamin participates in the early organization of the actin cytoskeleton during muscle
differentiation, although its final location in the Z-disc might be dependent on the presence of
myotilin. The expression of myotilin is tightly regulated to the later stages of in vitro
myofibrillogenesis, suggesting that myotilin could play a role in myofibril reorganization.
Premature expression of myotilin in muscle cells results in prominent actin cable formation, which
prevents normal assembly of sarcomeres. Furthermore, properly timed expression of truncated
myotilin fragments leads to severe disruption of myofibrils. All the characteristics of myotilin
support a role for myotilin as a "final lock" that enhances the thin filament cross-links and thus
provides rigidity and stability to the Z-disc structure. Mutation in the myotilin gene causes an
autosomal dominant form of limb girdle muscular dystrophy type 1A (LGMD1A). The identified
missense mutation results in the exchange of the amino acid 57 from threonine to isoleucine. The 57
kDa protein remains unaltered in the diseased muscles, whereas increased amounts of a 75 kDa
protein can be seen with myotilin antibody in western blot. The diseased muscles show extencive Z-
line streaming, which may be an indication of an altered function of myotilin.
Additional isoforms of myotilin (75, 42 and 35 kDa) have also been identified, although the 57 kDa
protein dominates in striated muscles. Moreover, the expression of different myotilin isoforms
seems not restricted only to striated muscles, but can also be seen in smooth muscle and epithelial
cells. Although these findings were not further explored in this study, they will provide the basis for
forthcoming experiments. Production of specific antibodies and RT-PCR based studies will finally
reveal the exact locations and roles of each isoform. Other important studies in future will be the
58
mapping of exact binding sites in myotilin and its binding partners, which will further define the
structure of the Z-disc. Also the mechanisms that regulate both myotilin expression and function are
of great importance. If myotilin is altered in VPDMD, the mutation(s) has to lie within the promoter
region, as all of the exons have already been sequenced. Thus the identification of the myotilin
promoter might also give insight to the molecular defect(s) behind VPDMD. Finally, a knock out
mouse model of myotilin, which already is under production, will provide information of the role
and function of myotilin in different tissues, especially in cardiac and skeletal muscles. On the other
hand, incorporation of the LGMD1A mutation to a knock out mouse may be the only way to find
out the pathogenic mechanism that leads to this disease.
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